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3. INTRODUCTION 
3.1 Epidemiology 
Primary central nervous system lymphoma (PCNSL) is a relatively rare type of primary brain tumor. 
It is defined as lymphoma occurring in the brain, leptomeninges, spinal cord or eyes without 
evidence of lymphoma outside the central nervous system.1,2 Prior to the 1980s PCNSL reportedly 
comprised approximately 1% of all brain tumors3-5 and 1% of all non-Hodgkin lymphomas.6 From 
early 1980s increasing incidence rates of PCNSL were reported both among acquired 
immunodeficiency syndrome (AIDS)-patients7,8 and in the non-AIDS population.4,7-10 However, 
increasing incidence rates were not found in all parts of the world. While increasing incidence rates 
were observed in the United States,4,7-10 the United Kingdom,11 the Netherlands,12 and Japan,13 stable 
incidence rates were found in Canada,14 Denmark,15 Scotland,16 Hong Kong,17 and India.18 Although 
most of these studies are population-based,4,7,8,10-17 none of the studies are based on the population of 
an entire country. No etiological factors that may explain the observed differences in incidence rates 
have yet been defined. Furthermore, some of the studies are based on recordings in registries without 
a review of the medical records.4,7,8,10,11  This may potentially have reduced the validity of their data; 
two studies report exclusion rates of above 50% after review of medical records.14,15 
During the last decades there have been discrepant reports concerning the relative frequency of 
PCNSL compared to primary brain tumors in general. Of all primary malignant brain tumors, 
PCNSL accounted for 1.2% at a hospital in India in 1985-1999,18 1.6% in a region of Denmark in 
1983-1992,15 5.1% in Southeast Netherlands in 1989-1994,12 and 6.6% at Massachusetts General 
Hospital in the US in 1978-1989.9 
Non-AIDS PCNSL 
The reported average annual incidence rate of non-AIDS-related PCNSL ranges from 1.0-4.8 per 
million in different studies during the last two decades. In a region of Denmark it was 1.6 per million 
in 1983-1992,15 in Hong Kong 1.0 per million in 1982-1997,17 and in Canada (Alberta) 1.1 per 
million in 1975-1996.14 In the US increasing incidence rates have been reported; 0.8 per million in 
1982-1984 (Surveillance, Epidemiology and End Results program; covering approximately 10% of 
the US population),4 2.0 per million in 1986-1989 (California, Florida, New Jersey and metropolitan 
Atlanta),7 and 4.8 per million in 1985-1997 (Surveillance, Epidemiology and End Results program; 
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excluding never-married patients and patients of unknown marital status to avoid possible human 
immunodeficiency virus (HIV)-infection).10 In Southeast England the average annual incidence rate 
of PCNSL was 2.1 per million in 1985-1990,11 and in Southeast Netherlands 2.7 per million in 1989-
1994.12 These two studies from England and Netherlands included some HIV-positive patients; 21% 
of the patients with available HIV status were HIV-positive in the study from England,11 whereas 
<15% of the patients were HIV-positive (estimated indirectly) in the study from Netherlands.12 As 
many studies are based on recordings in registries only,4,7,8,10,11 and some materials may have 
included patients with HIV-infection,11,12 former estimates on incidence rates may have been 
inaccurate.  
AIDS-related PCNSL 
PCNSL is an AIDS-defining disease,19,20 and it represents approximately 20% of all AIDS-related 
non-Hodgkin’s lymphomas (NHL).20,21 The absolute incidence rate of PCNSL per 1000 person-years 
among AIDS patients in the US was reportedly 4.7 in 1981-19907 and 8.4 and 1.1 in 1988-1995 and 
1996-2000,22 respectively. Incidence rates of PCNSL per 1000 person-years among HIV-infected 
individuals in Europe were 0.3-5.3 in 1983-2002,23 0.4-8.3 in 1994-2000,24 and 2.8 and 1.0 in 1993-
1994 and 1997-1998,25 respectively. PCNSL is diagnosed in approximately 2% of individuals 
infected with HIV,20,26 and in 9-14% of AIDS–autopsies.27-31 During the last decade, in the era of 
highly active antiretroviral therapy (HAART; introduced in 1996), the incidence of PCNSL among 
HIV infected patients has been reported to decline.19,22-25,32-35 However, few former studies on AIDS-
related PCNSL are population-based,7,21,22,29,36 and very few studies have presented findings in an 
entire country.36 
3.2 Etiology, pathogenesis and risk factors 
Immunocompromised patients have an increased risk for developing PCNSL. In this setting, PCNSL 
is typically secondary to AIDS, to iatrogenic immunosuppression for transplantation or for 
autoimmune diseases such as rheumatoid arthritis, or to congenital immunodeficiency syndromes.2,37-
39
 The life time risk for developing PCNSL is reported to be 1-5% for transplant patients, 1-2% for 
renal transplants recipients, and 2-7% for cardiac, lung or liver transplant recipients.39 Patients with 
congenital immune deficiency have an approximate 4% life time risk for developing PCNSL.39 
The etiology of PCNSL differs based on whether the affected patients are immunocompromised or 
immunocompetent. In the context of an immunocompromised patient, PCNSL normally arises from 
Epstein-Barr virus (EBV) infection of B lymphocytes.2,40 Affected B-cells proliferate unchecked by 
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the immune system and have a propensity to form tumors in the immuno-privileged environment of 
the central nervous system (CNS). The pathogenesis is unclear, but may involve cellular 
transformation by Epstein-Barr virus gene products, resulting in over-expression of bcl-2, a protein 
that inhibits apoptosis (programmed cell death).35 The association between lymphoma and EBV is 
striking in AIDS patients with PCNSL, and EBV is detected in almost 100% of the cases. This 
association with EBV is less pronounced in AIDS-related systemic non-Hodgkin’s lymphomas (20-
75% associated with EBV, depending on histological subtype).26 In AIDS patients, advanced disease 
with severe immunodeficiency with a very low CD4 cell count (less than 50/µL) is the most 
important predisposing factor for PCNSL.25,38 Among HIV-infected individuals in the French 
Hospital Database on HIV (for the time periods 1993-1994 and 1997-1998), the incidence rate of 
PCNSL was 9.7 and 0.15 /1000 person year at risk (PYAR) in patients with CD4 count <50/µL and 
>350/µL, respectively.25   
In contrast to immunocompromised patients, immunocompetent patients have no well-established 
cause of PCNSL. EBV and the human herpes viruses have been investigated, but no association with 
PCNSL has been discovered.31,37 As B-cells have no known role in the brain, it is puzzling how these 
neoplasms may develop. Some have proposed that PCNSL arises secondary to a systemic 
malignancy that is eliminated by the immune system, suggesting that neoplastic tumor cells have a 
propensity for the CNS since CNS offers immune protection.2,41 Others have hypothesized that 
trauma or infectious processes may attract lymphoid cells that proliferate locally to a monoclonal 
neoplastic state.41,42 Finally, it has been proposed that lymphomatous cells generated in other tissues 
might develop adhesion molecules and acquire selective homing receptors for cerebral 
endothelia.41,42 So far, no convincing data to support or refute any of these mechanisms have been 
published.  
Different from other lymphomas, there is no evidence to propose a hereditary component in the 
pathogenesis of PCNSL.40 However, PCNSL developing as a second neoplasm is reported in 8-13% 
of PCNSLs.43,44 This may represent an inherent individual predisposition to cancer, or it may be a 
consequence of the carcinogenic effect of the antineoplastic therapy administered for the first 
malignancy.40 PCNSLs among immunocompetent patients have a slight propensity for the male 
gender37,39 and the elderly population;37 there is no known disproportionate representation by race.37-
39
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3.3 Histopathology  
3.3.1 Establishing the diagnosis 
Confirmation of PCNSL is extremely important to facilitate early and optimal treatment. However, 
establishing the diagnosis may sometimes be difficult due to sites of involvement that are dangerous 
to biopsy or because of poor performance status of the patients. Modern immunohistochemical and 
molecular techniques make a diagnosis possible with a minimum of tissue sampled by stereotactic 
biopsy.40 There is broad consensus that if PCNSL is suspected, stereotactic biopsy is the diagnostic 
procedure of choice, since open neurosurgical resection does not add to survival and may increase 
functional deficits.31,45,46 Lymphoma cells may sometimes be detected through cytology of 
cerebrospinal fluid (CSF); reportedly tumor cells are detected in 5-35% of the cases.1,46-51 However, 
the diagnosis of PCNSL is normally established by cytological findings in less than 20% of 
PCNSLs, and the diagnosis of PCNSL, thus, mainly relies on histological analysis of tissue 
samples.1,46 In some patients, the first stereotactic or open biopsy is unrewarding and a second biopsy 
has to be done.2,52 In these cases, pre-biopsy treatment with systemic corticosteroids may have 
obscured the diagnosis.46,52,53 For this reason, the diagnosis should be established before the 
initiation of steroid treatment.2,53 For a subset of patients with ocular symptoms, vitrectomy or 
choroidal/retinal biopsy may sometimes establish the diagnosis of intraocular PCNSL, making 
stereotactic or open biopsy unnecessary.54,55  
AIDS-related PCNSL may occasionally be diagnosed without biopsy, based on the detection of CSF 
EBV DNA, but this test is not completely specific.26,28 Biopsy is normally needed, but should be 
weighted against its relatively high procedural risk in AIDS patients, with a reported postbiopsy 
morbidity of 8% and postbiopsy mortality of 3%.26,56  
3.3.2 Histopathological findings in immunocompetent patients 
Histologically, PCNSLs resemble systemic lymphomas, although a greater proportion of PCNSLs 
are high-grade lymphomas.57 More than 95% of the PCNSLs are B-cell lymphomas.50 
Intraparenchymal lymphomas, representing the majority of cases, are nearly always diffuse in 
architecture.57 Different classification systems including the Kiel-, the Working Formulation-, the 
Revised European-American Lymphoma- (REAL) and the WHO-classifications have been applied to 
PCNSL during the last decades, but none of these classifications specifically deals with PCNSLs.50 
The application of The Kiel Classification (common PCNSL subtypes: immunoblastic, centroblastic, 
lymphoblastic or low-grade lymphomas) and the Working Formulation Classification (common 
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PCNSL subtypes: diffuse large cell, diffuse large cell immunoblastic, diffuse small cleaved cell, 
small non-cleaved cell/non-Burkitt’s, unclassifiable, and diffuse mixed small and large cell), has 
proved unreliable and unsuitable for PCNSL.42 When using the REAL or closely related WHO 
classification schemes, diffuse large B-cell lymphomas account for 90-95% of all PCNSLs.57,58 
Rare pathological variants include low-grade PCNSL of either B- or T-cell origin found in 
approximately 3% of PCNSLs57,59 and T-cell lymphomas found in 2-4% of PCNSLs in Western 
countries.45,50,60 The proportion of T-cell lymphomas might be somewhat higher in Asia; T-cell 
lymphomas represented 9% and 17% of PCNSLs in studies from Japan61 and Korea,62 respectively. 
Other rare histological subtypes of PCNSL include Burkitt PCNSL, lymphomatosis cerebri, primary 
intraocular lymphoma, neurolymphomatosis (infiltration of the peripheral nervous system by 
lymphoma), pituitary PCNSL, solitary intracranial plasmacytoma, Hodgkin lymphoma, intravascular 
lymphoma (involving the small vessels of the brain exclusively), and dural low grade B-cell 
marginal zone lymphoma (MZL), also denoted mucosa-associated lymphoid tissue (MALT) 
lymphoma of the intracranial dura.1,40,50,54,55,57,58,63   
3.3.3 Histopathological findings in immunodeficient patients 
In the context of immunodeficiency, PCNSL is almost always associated with EBV, whereas in 
immunocompetent individuals, EBV-associated PCNSL is very rarely seen.2,26,40,57,64 In 
immunodeficient PCNSL patients the lesions are more often multifocal and necrotic compared to 
lesions in immunocompetent patients.26,57,65-67 Histopathologically the EBV-related PCNSLs are 
quite similar to non EBV-related PCNSLs;57 both are most often high-grade diffuse large B-cell 
lymphomas.26 Low grade lymphomas occur less frequently in AIDS patients than in 
immunocompetent individuals.57   
3.3.4 Tumor biomarkers and histogenetic origin 
The expression of different tumor biomarkers and its impact on survival in PCNSL have been 
increasingly explored during the last decade.68-72 The histogenetic origin of PCNSL with respect to 
stage of B-cell differentiation has been elucidated by using panels of immunohistochemical markers. 
CD10 and Bcl-6 are expressed in germinal center B (GCB) cells whereas MUM1 (multiple 
myeloma-1) and CD138 are expressed in activated B-cells.68 High expression of Bcl-6 has been 
linked to a likely GCB origin.68,72,73 Genetic studies have also suggested PCNSL to be derived from a 
late GCB cell.74,75 The majority of PCNSLs express MUM1 and Bcl-6.68,76 Based on these findings 
of antigens characteristic of late GC and early post GC, a histogenetic origin of PCNSL in a “time-
slot” overlapping late GC and early post GC has been postulated (Figure 1).68  
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Figure 1 
Schematic presentation of hypothesis to explain the histogenesis of PCNSL developed by Camilleri-
Broet et al.68  GC, germinal center; MUM1, multiple myeloma-1.  
3.3.5 Tumor biomarkers as prognostic markers 
Different tumor biomarkers have been explored in PCNSL, to identify any prognostic impact of the 
expression of these markers. The antiapoptotic protein Bcl-2 is associated with poor outcomes in 
systemic NHL,77 but not in PCNSL.64,71 In systemic NHL, expression of GC phenotype (Bcl-6 and/or 
CD10) is associated with favorable outcome69,77 whereas in PCNSL, Bcl-6 expression has been 
associated with better outcome in some studies,69,72,76 but not in all.68,71,78 P53 and Ki-67 have no 
prognostic impact in PCNSL in two reports,64,79 but they were associated with poorer survival in one 
study.71 Vascular endothelial growth factor (VEGF) and endoglin (CD105) are markers of 
angiogenesis in PCNSL; VEGF expression was associated with longer survival,70 and low 
intratumoral microvessel density (IMVD) using CD105 immunostaining, was a favorable prognostic 
factor.80  
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3.4 Clinical features 
3.4.1 Age and gender 
In immunocompetent patients, the median age at diagnosis of PCNSL is 55-60 years.37,38,40,45,46,61,81 
Among AIDS patients, PCNSL presents earlier at a median age of 35-39 years21,33,39 and a mean age 
of 31-37 year.33,38,39,65,81 Pediatric cases of PCNSL are rare and constituted 1.5% and 1% of PCNSLs 
in Japan (Brain Tumor Registry; 1969-1990)82 and the US (the Surveillance, Epidemiology and End 
Results program; 1973-1998),83 respectively. As in adults, PCNSL occurs more frequently in 
immunodeficient children.84  
A male predominance with a male/female ratio of 1.2-2.0:1 in immunocompetent patients, is 
reported in most studies;11-14,18,38,40,48,60,61,81 however, no male preponderance has also been 
reported.15,17 The male/female ratio of AIDS-related PCNSL is reportedly 7:1.65 
3.4.2 Symptoms 
As with all lesions in the CNS, the location of the PCNSL lesions determines the clinical 
presentation. The most common symptoms are neurological deficits, reported in 50-70% of 
cases.40,45,65 Hemiparesis or motor dysfunction are reported in 11-52%.46 Cognitive, behavioral, and 
personality changes are frequently reported (in 24-73%);45,46 these symptoms may be somewhat more 
prevalent in AIDS-related PCNSL65 and are related to tumor location in the corpus callosum and 
deep frontal lobes.37 Signs of increased intracranial pressure such as headache, nausea, vomiting, or 
papilloedema are reported in 14-45% of PCNSLs and ataxia or cerebellar symptoms in 15-
42%.33,45,46,65 Seizures are relatively uncommon in non-AIDS PCNSLs (in the order of 12-14%),45,65 
but are more common in AIDS-related PCNSLs (in 22-27%).33,65 Symptoms of visual disturbance are 
present in 8-20% of immunocompetent patients with PCNSLs; these visual symptoms include 
blurred vision, decreased visual acuity, floaters, and painful red eyes, misleadingly suggestive of 
uveitis or inflammatory diseases.37,38,46 Primary intraocular lymphoma, a rare subset of PCNSL 
defined by intraocular lymphoma with or without central nervous system involvement, is 
occasionally diagnosed in the patients presenting with visual disturbance.54,55 
3.4.3 Time from symptoms to diagnosis 
The reported median duration of symptoms prior to the histological diagnosis of non-AIDS PCNSL 
is 1.5-5 months47,85,86 while mean duration from debut of symptoms to histological diagnosis of 
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PCNSL is 3 months in non-AIDS patients and 2 months in AIDS patients.65 Administration of 
corticosteroids may delay or confound the diagnosis due to cytolysis of lymphoma cells.53   
3.4.4 Cerebrospinal fluid findings 
A lumbar puncture for CSF examination should be performed on patients with suspected PCNSL, 
but only in patients having no increased risk of cerebral herniation due to increased intracranial 
pressure. An examination of CSF includes: 1) basic studies of white blood cell count, protein and 
glucose concentrations; 2) cytology and flow cytometry; and 3) polymerase chain reaction (PCR) for 
clonal immunoglobulin gene rearrangements - or in AIDS patients, PCR for EBV DNA.38,46,81  
Basic CSF parameters, such as white blood cell count and protein and glucose concentrations, may 
be normal or slightly abnormal, indicating non-characteristic changes. White blood cell count, total 
protein, albumin, IgG, or lactate are elevated in 40-85% of the patients,38,40,46-49,51,81 and decreased 
glucose concentrations are found in 0-13%.38,46,48,51,81,87  
Cytological studies of CSF may in some instances be sufficient to confirm the diagnosis of PCNSL. 
Lymphoma cells in CSF are identified in 5-35% of immunocompetent patients with PCNSL.1,38,46-
51,65
 Serial CSF samples may be required to make a diagnosis of PCNSL through CSF cytology since 
the initial cytology is negative in two thirds of the patients who finally have a positive CSF 
cytology.38 Treatment with steroids prior to CSF sampling may induce a falsely negative CSF 
cytology.38,88 In AIDS-related PCNSL with leptomeningeal dissemination (in 25% of AIDS-related 
PCNSLs), 50% and 85% of the cases have positive CSF cytology after one and three samplings, 
respectively,26 and positive cytology of CSF has been found in 23% (3/13 patients) in one study.65 
The value of DNA flow cytometry in the diagnosis of PCNSL is limited by the low cell count of 
most CSF specimens, and this test rarely adds additional diagnostic information.38,51   
PCR examination of the CSF is an important complement to cytology, as it sometimes provides the 
correct diagnosis when conventional cytology only yields ambiguous results. Demonstration of 
clonal rearrangements of immunoglobulin genes can establish monoclonality of the lymphocyte 
population, and can thus make the diagnosis of PCNSL.89 However, the sensitivity and specificity of 
CSF PCR as diagnostic tool for non-AIDS PCNSL is uncertain.38 In AIDS patients, detection of 
EBV DNA in CSF may establish the diagnosis of PCNSL and obviate the need for biopsy.26,26,38 A 
sensitivity of 80-100% and a specificity of 79-100% of CSF PCR testing for EBV DNA have been 
reported.26,90,91 Positive EBV PCR in CSF may also be found in patients with AIDS-related systemic 
lymphoma; it may be detected preclinically, several months prior to the symptoms of AIDS-related 
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PCNSL or systemic AIDS-related lymphoma with CNS disease.26,91 Further, PCR detection of 
Toxoplasma gondii DNA in CSF may be helpful in differentiating PCNSL from cerebral 
toxoplasmosis; the most common cause of intracranial mass lesions in adult AIDS patients.26,92,93  
3.5 Imaging characteristics 
PCNSL may have a characteristic appearance on both CT and MR imaging. This is due to its 
hypercellularity, high nuclear/cytoplasmic ratio, disruption of the blood-brain barrier, and its 
predilection for the periventricular regions.38,81,94,95  
3.5.1 Appearance in immunocompetent patients  
Previous studies indicate that PCNSL typically presents as a solitary, homogeneously enhancing 
mass.66,101-103 Multiple lesions are reported in 20-40% of non-AIDS PCNSLs,45,47,48,61,65,86,97-100,103,104 
and ring-like enhancement is observed in 0-11% of the patients.48,65,66,96,99,100 Perifocal oedema is 
usually present but less prominent than in malignant gliomas or metastases.31 Most lesions are 
located central hemispheric or periventricular in cerebral white matter.95,105 Frontal lobe location is 
reported in 20-30% of PCNSLs,45,48,96,100 and the basal ganglia are affected in 12-33% of the 
patients.45,48,95-99 The brain stem and/or cerebellum are affected in 9-13%;45,47,48,94,98,101 the spinal 
chord in only 1-2% of the patients.98,99 Hemorrhage within the tumor is reported in 0-4%,14,97,100 but 
has been reported in 21% (4/19 lesions) in one small study.106 Internal calcification within the 
PCNSL lesion is observed in 2-3% in some studies on primary imaging.14,97,100 
Imaging findings in non-AIDS PCNSL have mostly been investigated in single- or multicenter 
studies.45,48,96-102 In immunocompetent patients, population-based studies on such findings are 
scarce.14 Also, with increasing incidence of PCNSL and advancing imaging technology, typical 
appearance at CT and MR imaging may have changed. However, no previous study has explored 
temporal trends in imaging findings in non-AIDS PCNSL.   
3.5.2 Appearance in immunodeficient patients  
Compared to immunocompetent patients with PCNSL, immunodeficient patients with PCNSL are 
more often diagnosed with multifocal lesions, which are reported in 30-80% of  patients with AIDS-
related PCNSL.33,65,105,107-110 Since many lesions exhibit necrotic regions, contrast enhancement is 
commonly irregular or peripheral, and ring-like enhancement is reported in as much as 50% of the 
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cases in some reports.65,110 The basal ganglia and corpus callosum are frequently involved.105,110 
Spontaneous hemorrhage in PCNSL lesions may be more frequent in AIDS patients than in non-
AIDS patients,111 and was identified in as much as 35% (7/20) of the AIDS patients at MRI in one 
study.110 Imaging findings in AIDS-related PCNSL reported in the literature are all based on single 
or multi-center studies;33,65,105,107-110 no study has been population-based. 
3.5.3 CT features 
In both immunocompetent and immunodeficient patients with PCNSL, unenhanced computerized 
tomography (CT) typically reveals hyper- or isodense lesions, and virtually all lesions show 
enhancement after administration of contrast.94-97,111,112 Negative findings from CT examinations, 
however, do not exclude PCNSL since false-negative initial CT examinations are also 
reported.95,107,113 Whether CT findings of PCNSL have changed with advancing CT technology has 
not formerly been studied. 
3.5.4 MR imaging features  
In both immunocompetent and immunodeficient patients with PCNSL, lesions are typically hypo- or 
isointense on unenhanced T1 weighted MR imaging.94-97,105,112 On T2 weighted images, most papers 
describe lesions as iso- to hyperintense;47,66,96,102,106,110,114,115 some studies also report hypo- or 
isointense lesions to be a frequent finding.66,94,95,103 Most lesions show marked contrast enhancement 
at MR imaging.94-99,105,109,112 No enhancement at contrast enhanced MR imaging or isolated white 
matter hyperintensity on T2 weighted MR imaging has also been described in some rare cases of 
PCNSL.116,117 Traditional MR imaging findings in PCNSL may have changed in the era of increasing 
incidence of PCNSL and improved MR imaging technology; this issue has not been previously 
addressed. 
Due to the relative restriction of water diffusion within PCNSLs, lesions typically appear 
hyperintense on diffusion-weighted images (DWI) and hypointense on apparent diffusion coefficient 
(ADC) maps.38,114,118 This characteristic is shared by acute ischemic stroke, brain abscess and high-
grade neoplasms.38,118-121 The diffusion within a PCNSL lesion is typically more restricted than in 
most other brain malignancies, demonstrated by lower ADC values in PCNSL lesions compared to 
high-grade gliomas and metastases.122,123 Intracranial abscesses normally have lower ADC values 
than most brain tumors.121,123,124 Proton (hydrogen-1) MR spectroscopy has demonstrated elevated 
lipid resonances with high choline (Cho)/creatine (Cr) ratios in PCNSL.99,115,125-127 Perfusion-
weighted images (PWI) in PCNSL demonstrate low maximum cerebral blood volume ratios in tumor 
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and a characteristic intensity time-curve that is related to a massive leakage of contrast media into 
the interstitial space.114,128 
3.5.5 Metabolic imaging 
F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) demonstrates increased uptake 
of  FDG in non-AIDS PCNSL.95,129-131 After steroid treatment the degree of hypermetabolic activity 
in PCNSL decreases and resembles that of malignant glial tumors.132 FDG-PET may be suitable for 
early evaluation of therapeutic response.129,130 High N-isopropyl-p-[123I]-iodoamphetamine retention 
on single-photon emission CT (SPECT) is identified in non-AIDS PCNSL lesions; this may 
reportedly aid in the diagnosis of PCNSL.133   
Thallium-201 SPECT, single photon emission tomography (SPET) and FDG-PET may be useful 
adjuncts to MRI in patients having AIDS and focal intracranial lesions.134,135 While infections 
normally are hypometabolic, PCNSLs are hypermetabolic with a high Thallium-201 uptake ratio on 
SPECT and SPET26,134,135 and high  FDG uptake on PET.26,136-138  
3.5.6 Differentiation of PCNSL from other diagnoses by imaging 
Non-AIDS PCNSL 
In immunocompetent patients, the typical characteristics of PCNSL at standard CT and MRI are not 
always present; even when present, none of these characteristics will unequivocally differentiate 
PCNSL from other neoplasms (e.g. metastases, malignant gliomas, meningiomas) or non-neoplastic 
diseases (e.g. multiple sclerosis, stroke, pyogenic abscess). Newer MR imaging methods that may 
help to differentiate PCNSL from other lesions of the brain are DWI,95,122,123 PWI,114,122,128 and MR 
spectroscopy.125,126 A new MR imaging contrast agent (iron oxide nanoparticles) seems promising in 
the differentiation of malignant neoplasms from multiple sclerosis.139 Furthermore, FDG-PET and N-
isopropyl-p-[123I]-iodoamphetamine SPECT may aid in the identification and differentiation of 
PCNSL from malignant gliomas and meningiomas.129-131,133  
AIDS-related PCNSL 
The traditional CT and MR imaging findings of AIDS-related PCNSL are similar to those in cerebral 
toxoplasmosis.26,26,109,111 Diffusion weighted MR imaging shows significantly overlapping ADC ratios in 
toxoplasmosis and lymphoma, making DWI unreliable in the differentiation of PCNSL from cerebral 
toxoplasmosis.118 MR spectroscopy has proved to aid in the differentiation of focal brain lesions in 
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AIDS patients in some studies,115,140 but not in all.141,142 PWI has been rather disappointing in this 
aspect.109 T1-201 SPECT and SPET have been shown to be very accurate in the differentiation of AIDS-
related PCNSL from toxoplasmic encephalitis in some studies,111,134,142 but less reliable for this 
differentiation in other studies.26,135,143 SPECT loses accuracy when the lesions are small (<6-8mm), 
located leptomeningeal, subependymal, or near the base of the skull, or when the patient has been 
treated with steroids.111 FDG-PET is a promising adjunctive diagnostic tool that may aid in the 
differentiation of infectious and non-infectious brain masses in AIDS.26,109,111,136-138   
Although some of these newer imaging methods can help to differentiate PCNSL from other lesions 
both in immunocompetent and immunocompromised patients, none of these methods have a well-
defined role in the diagnosis of PCNSL. Further studies are needed to fully explore the diagnostic 
potential of these imaging methods as well as their ability to monitor therapeutic response in 
PCNSL. Furthermore, although the methods seem promising, they are not generally available at most 
medical centers. Thus, in most clinical settings, diagnostic imaging of PCNSL still relies on 
traditional CT and MR imaging.  
3.6 Staging 
By definition, PCNSL implies the absence of systemic lymphadenopathies and other extracranial 
localizations of lymphoma. Therefore, PCNSLs are stage IE (single extralymphatic organ) according 
to the Ann Arbor staging system.144 However, large or multifocal masses are normally classified as 
stage IV (diffuse or disseminated involvement of one or more extralymphatic organs or tissues).88,145 
After the diagnosis of PCNSL has been established, based on biopsy specimen or analysis of CSF or 
vitreal aspirate, a staging evaluation should be performed (Table 1).2,81,146 This should include a 
comprehensive physical and neurologic examination.147 Staging for extent of central nervous system 
involvement includes: 1) Contrast enhanced MR imaging of the brain and of the spine when 
clinically indicated. 2) Ophthalmologic evaluation, including slit-lamp examination, to detect ocular 
involvement. 3) CSF cytology, cytometry, and analysis of total protein, for the identification of 
leptomeningeal involvement. CSF tumor markers such as lactate dehydrogenase (LDH) isoenzyme 5, 
ß- glucuronidase, and ß2-microglobulin may also be evaluated.2,37  
Occult systemic lymphoma has been reported in up to 13% of patients initially thought to have 
isolated PCNSL,147-150 and a complete systemic staging is therefore warranted. CT of the 
chest/abdomen/pelvis and a bone marrow biopsy should be performed routinely to rule out systemic 
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NHL.2 All patients should be tested for HIV since a diagnosis of PCNSL in the setting of HIV has 
important implications for treatment and prognosis. 18FDG PET may be more sensitive than 
conventional staging with body CT and bone marrow biopsy for detection of systemic lymphoma,151 
and 18FDG PET may be incorporated into the evaluations of systemic disease in the future.147 
Testicular ultrasound may be performed to rule out testicular lymphoma that has metastasized to the 
brain, and serum LDH may be measured since this parameter may be a prognostic factor in 
PCNSL.37,81,147 Recently, subclinical systemic disease in PCNSL was detected by PCR of the 
rearranged immunoglobulin heavy-chain (IgH) genes in 8% (2/24) of the patients.152 However, the 
clinical implication of this occult systemic involvement, not detectable by routine staging, remains 
unknown. 
 
 
 
 
 
 
 
 
 
 
 
3.7 Treatment  
3.7.1 Treatment of non-AIDS PCNSL 
Corticosteroids 
Corticosteroid therapy may result in rapid resolution of cerebral mass lesions in PCNSL and is often 
associated with clinical improvement.53 Corticosteroids are potent inducers of apoptosis in lymphoid 
cells, resulting in cytotoxic effects rather than a reduction of cerebral edema.37 A marked 
improvement or resolution of lesions after the start of corticosteroids occurs in at least 40% of 
PCNSL patients.153 Neuroimaging response may be dramatic, sometimes demonstrating complete 
Table 1 
Recommended diagnostic evaluation at time of histological diagnosis of PCNSL2  
  
  CNS staging 
 Contrast enhanced MRI of the brain 
 Contrast enhanced MRI of the spine when clinically indicated 
 Lumbar puncture for CSF protein and cytology 
 Ophthalmologic evaluation with slit lamp 
  Systemic staging 
 Computed tomography of chest/abdomen/pelvis 
 Bone marrow biopsy 
 HIV testing 
 Serum LDH 
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remission of contrast-enhancing lesions within a few days of glucocorticoid treatment.53 However, 
most responses are temporary, and recurrence of PCNSL normally occurs during glucocorticoid 
withdrawal or during chronic glucocorticoid treatment.53  
Although a marked glucocorticoid response may be suggestive of PCNSL, it is not diagnostic of 
PCNSL since other processes, such as multiple sclerosis or neurosarcoidosis, can respond similarly 
to corticosteroids.53,153,154 Furthermore, treatment with corticosteroids prior to biopsy/cytology may 
obscure the diagnosis; thus, steroids should be avoided in suspected PCNSL until the diagnosis has 
been established.2,46,52,53,53,153,155 When increased intracranial pressure necessitates therapy, osmotic 
agents such as mannitol, should be considered prior to histological diagnosis.53 When the 
histological diagnosis of PCNSL has been established, glucocorticoid treatment may relieve 
symptoms. The lowest possible dose should be given for as short a period as possible to avoid the 
prominent side effects of long-term glucocorticoid treatment.37    
Surgery 
There is no known survival benefit to debulking surgery other than in patients who have masses 
large enough to cause herniation.37 Furthermore, surgical resection may increase functional 
deficits.45,46 The primary role of surgery, therefore, is to obtain an appropriate and adequate sample 
of tissue with stereotactic needle biopsy; this method is ideal for evaluating malignancies that lie in 
or adjacent to deep structures of the brain.2  
Radiotherapy 
Radiotherapy is a fundamental part of PCNSL therapy. Based purely on CT and MR imaging, one 
would presume that PCNSL is a well-circumscribed disease suitable for focal radiotherapy. 
However, autopsy studies have demonstrated that PCNSL extensively infiltrates the brain 
microscopically; this microscopic tumor probably exists behind an intact blood-brain barrier.156 MR 
imaging has also been shown to underestimate the tumor burden of PCNSL compared to autopsy 
findings, since microscopic tumor infiltration of lymphoma at autopsy was seen as isolated T2 
hyperintensity or was completely normal at MR imaging.116 Consistent with these findings, patients 
receiving focal radiotherapy may experience recurrence of the disease within and outside the 
radiation field.157   
Throughout the 1980s whole brain radiation therapy (WBRT) was the mainstay of treatment for non-
AIDS PCNSL.158-162 Whole brain irradiation as sole treatment normally induces temporary tumor 
regression with a reported median survival time of 12-18 months153,158,161,163,164 and 5-year survival 
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below 20%.163 The addition of chemotherapy to standard radiotherapy has had an appreciable 
positive impact on tumor response and patient survival.104,161,165-170 The optimal dose of radiotherapy, 
as sole treatment or combined with chemotherapy, is however, not definitely established. Patients 
receiving less than 40 Gy may have shorter survival,170,171 whereas patients receiving more than 50 
Gy may have higher risk of late neurotoxicity.104 The addition of focal boost towards tumor has not 
proved beneficial for survival.164 A dose of 45 Gy whole brain irradiation with no boost is currently 
recommended by some authors.37 Combined treatment with WBRT and chemotherapy may cause an 
unacceptably high incidence of severe permanent neurotoxicity, particularly in patients aged > 60 
years.172,173 In older patients, deferred whole brain radiotherapy does not seem to compromise overall 
survival; this has made some authors suggest deferring radiotherapy in elderly in an effort to 
minimize this treatment related neurotoxicity.155,169,173-176 Ongoing protocols are further examining 
the option of either deferring radiotherapy or using a lower dose in the elderly and in patients with 
complete response on chemotherapy.37  
Chemotherapy 
PCNSL is an exquisitely chemosensitive tumor, and the addition of chemotherapy to radiotherapy 
has substantially improved survival.2,167-169 Different chemotherapeutic regimens have been applied 
with chemotherapeutic agents from a variety of classes; antimetabolites (cytarabine, methotrexate), 
corticosteroids (dexamethasone, hydrocortisone, methylprednisolone), alkylating agents (busulfan, 
carmustine/BCNU, cyclophosphamide, ifosfamide, lomustine, melphalan, procarbazine, 
temozolomide, thiotepa), topoisomerase inhibitors (etoposide, teniposide, topotecan), microtubular 
poisons (vincristine), mitotic inhibitor (vindesine), antitumor antibiotics (idarubicin), and 
monoclonal antibodies (rituximab).169,177-180 Early reports used common systemic NHL regimens like 
cyclophosphamide, doxorubicin, vincristine, and prednisone/dexamethasone (CHOP/CHOD). 
However, post- or preirradiation chemotherapy with CHOP/CHOD did not significantly improve 
survival over radiotherapy alone and tended to give short-lived responses.181-184 Furthermore, patients 
experienced significant treatment related toxicities.183,185 This lack of benefit of CHOP/CHOD may 
be partially attributed to the poor penetration of the blood-brain barrier by these agents, and this 
chemotherapy regimen has no longer any role in the treatment of PCNSL.169 
High-dose methotrexate 
The history of chemotherapy for PCNSL to date has culminated in the finding that intravenous (IV) 
high-dose methotrexate (HD-MTX; dose ≥ 1g/m2) is the most effective drug against PCNSL. HD-
MTX based regimens are the only regimens with a significant advantage over radiotherapy 
alone,146,169,178 and most neurooncologists advocate utilizing HD-MTX as a platform for the 
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chemotherapy treatment of PCNSL.186 Several HD-MTX based combinations have been assessed in 
trials, but the superiority of additional drugs over HD-MTX alone is not unequivocally 
demonstrated.146,177,178 However, in a large multicenter study of treatment of PCNSL, the addition of 
HD-cytarabine to HD-MTX significantly improved survival.187 During the last decade, a large 
number of different regimens have been reported in which HD-MTX is used as initial 
treatment.168,173,177,188-202 Varying treatment regimens and differences in patient selection, however, 
make the comparisons of survival in these clinical trials difficult.  
HD-MTX as single agent with a dose of 8g/m2 without WBRT has been applied with median 
survival rates of 25-55 months.194,196 Single agent HD-MTX at lower doses (1-3.5g/m2) combined 
with WBRT has resulted in a median overall survival of 20-41 months in older studies.166,178,205 
Treatment with HD-MTX (1-5g/m2) combined with a variety of chemotherapeutic drugs, with or 
without radiotherapy, has given a reported median survival of 12-60 months in different recent 
studies.173,177,188-190,192,193,197,198 The choice of additional drugs for these regimens has been based on 
their activity in non-Hodgkin lymphoma and their ability to penetrate an intact BBB.178  
There is almost a complete lack of prospective randomized trials on PCNSL,184,203 and the optimal 
chemotherapy treatment remains controversial.178 Furthermore, as patients participating in clinical 
trials often are highly selected with younger age and better performance status than the general 
patient population, the results from these trials may not be applicable to a standard clinical setting. 
Retrospective studies exploring treatments and outcome in population-based materials of non-AIDS 
PCNSL are scarce,162,204 but such studies may be valuable since they evaluate outcomes in a standard 
clinical population-based setting unaffected by any clinical study.  
Chemotherapy dose intensification 
Much of the focus of current research is on optimizing chemotherapy and allowing patients to defer 
radiotherapy and its sequelae. In an attempt to enhance the delivery of therapeutic agent to the brain 
while preserving neurocognitive function, treatment with intra-arterial (IA) HD-MTX in conjunction 
with blood-brain barrier disruption (BBBD) with hyperosmolar agents (mannitol) has been studied in 
PCNSL.197,206-208 Response rates are comparable to treatment with IV HD-MTX, and WBRT might 
be obviated or postponed in a substantial number of patients.208 Furthermore, long term survival with 
preserved cognitive function is possible.208 However, this treatment is only feasible at specialized 
centers and is procedurally very intensive with intraarterial catheterization under general anesthesia, 
monthly, over a year.207 
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Myeloablative doses of chemotherapy, inducing a severe or complete depletion of bone marrow 
cells, followed by autologous stem cell rescue (ASCR) has proved to be successful in systemic 
NHL.209 The aim of such treatment in PCNSL is to attain cure with cytotoxic therapies alone, 
allowing patients to avoid radiation-induced long-term neurotoxicity. Recent studies of HD 
chemotherapy supported by autologous stem cell transplantation (ASCT) in PCNSL report median 
survival of 20-63 months.199-202  
Intrathecal chemotherapy 
The need for intrathecal (IT) chemotherapy for PCNSL is controversial. Some successful regimens 
have included the use of intrathecally delivered MTX and/or cytarabine, but this is associated with 
significant morbidity due to arachnoiditis, infection, bleeding, leucoencephalopathy, and other 
complications related to Ommaya reservoir placement or repeated lumbar punctures.178 IV high-dose 
MTX and cytarabine are known to produce tumoricidal levels within the CSF, and it has been 
questioned whether IT drug administration is a crucial part of PCNSL therapy. Some studies have 
failed to demonstrate any benefit from IT MTX when added to HD IV therapy,187,210 but these 
findings have not been validated in prospective randomized studies. Some authors reserve IT 
chemotherapy for patients with a positive CSF cytologic examination.169 However, as the sensitivity 
of cytological examinations of CSF is low, negative CSF cytology may be a rather unreliable 
parameter for treatment decisions.  
Salvage therapy 
More than half of the patients achieving remission on primary treatment eventually relapse. At 
recurrence the patients should be re-staged and considered for salvage therapy which has been 
shown to improve survival in relapsing PCNSL.169,211,212 The optimal salvage treatment is, however, 
not yet established.213 Available options for refractory or recurrent PCNSL include WBRT, 
chemotherapy, and ASCT.178,214 The type of first-line treatment used provides important therapeutic 
and prognostic implications in relapsing PCNSL. Patients relapsing after a chemotherapy-only initial 
treatment may respond to salvage radiotherapy, although this gives an increased risk of 
neurotoxicity.196,200,211,215,216 In patients achieving complete response at initial treatment with HD-
MTX based chemotherapy, salvage HD-MTX at relapse may be effective with a reported median 
survival of 62 months from first relapse,217 but this treatment is normally only feasible in younger 
patients with good performance status. Various non-MTX based regimens including single agent 
temozolamide218,219 or topotecan,220,221 combined chemotherapy regimens,222,223 or intraarterial 
chemotherapy with BBBD224 have been tried as salvage treatment for PCNSL, resulting in median 
survival rates of 4-32 months.  
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Acute and chronic toxicity 
Therapy for PCNSL may be well tolerated in the acute setting, but all therapies are associated with 
some side effects. During radiotherapy some patients experience significant fatigue, and some 
patients experience worsening neurologic deficits due to edema.37 Common acute side effects of 
chemotherapy are related to bone marrow suppression (leading to anemia, leukopenia, and 
thrombocytopenia) and nephrotoxicity (leading to acute renal failure).186 IV MTX may cause 
transient encephalopathy characterized by mental status changes, lethargy, and somnolence several 
days after treatment,37 and IT MTX may lead to arachnoiditis.178   
During the last decades there has been an increasing concern regarding the disabling long term 
effects observed in patients treated for PCNSL.172,225-227 Neurotoxicity, which is considered the most 
frequent complication in long-term survivors, is a syndrome characterized by rapidly progressive 
subcortical dementia with psychomotor slowing, executive and memory dysfunction, behavioral 
changes, gait ataxia, and incontinence.226 Neurotoxicity reportedly affects 24-58% of the patients 
treated with the combination of chemotherapy and radiotherapy.104,168,226,228,229 Chemotherapy and 
WBRT may both cause CNS damage, but there is a synergistic toxic effect when these two 
modalities are combined.172 The prevalence of neurotoxicity appears to increase with age and 
radiation dose. In patients aged >60 years, neurotoxicity following combined chemo- and 
radiotherapy may affect up to 90% of those undergoing treatment.173 Given this great risk of 
neurotoxicity in the elderly, patients above 60 years of age are often treated with chemotherapy 
alone.  
Neuroimaging in patients with treatment-related neurotoxicity often shows diffuse 
leukoencephalopathy, atrophy, and communicating hydrocephalus with white matter hyperintensity 
on T2-weighted MR imaging.230 In patients treated with MTX-based chemotherapy without WBRT, 
the risk of long-term neurotoxicity is very low, and the MTX-induced white matter changes 
detectable on MR imaging in these patients do not seem to be associated with a cognitive 
decline.231,232 
In order to effectively monitor and compare the extent of neurotoxicity in different clinical trials, it 
is strongly recommended that baseline neuropsychological tests are performed before, during, and 
after treatment of PCNSL.146,233  
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3.7.2 Treatment of AIDS-related PCNSL  
With supportive care only the median survival in patients with AIDS-related PCNSL is 1-1.5 
months.20,65,234 Palliative WBRT has been the mainstay of treatment in AIDS patients resulting in 
median survival of 2.0-5.5 months.26,33,65 HAART should be considered in all patients with AIDS-
related PCNSL as prolonged survival has been observed with the administration of HAART.33,234-236 
The role of chemotherapy in AIDS-related PCNSL has so far been very limited since most AIDS 
patients are ineligible to chemotherapy due to factors such as concurrent infections, progressive 
neurologic deterioration, and poor performance status.26 Survival of more than one year is, however, 
occasionally achieved in selected patients who are eligible to chemotherapy.20,26,237,238 Lately, there 
has been a considerable interest in EBV-targeted therapies in AIDS patients,26,239-241 but their 
application in AIDS-related PCNSL is not yet fully established.    
3.8 Outcome 
Non-AIDS PCNSL 
The prognosis of non-AIDS PCNSL in patients receiving only symptomatic therapy is extremely 
poor with a median survival of 2-3 months.65,87 Patients treated with whole brain irradiation as sole 
treatment have a reported median survival time of 12-18 months65,153,158,161,163,164,242 and 5-year 
survival below 20%.163,242 Combined radiotherapy and chemotherapy has substantially improved 
survival during the last decades with reported median survival of up to 63 months.167,168,173,188,189,191-
193,200,202,228,243
 Chemotherapy alone has also a well-documented effect on non-AIDS PCNSL194-198 
with reported median survival of up to 55 months.194,195 To minimize treatment related neurotoxicity, 
deferred whole brain radiotherapy in older patients might be a favorable option as this does not seem 
to compromise overall survival.155,169,173-175 In younger patients, however, chemotherapy-only 
regimens seem to be associated with shorter progression free survival times and decreased potential 
for cure, supporting the use of WBRT in addition to chemotherapy in younger patients.178 
Survival rates reported in the literature are mostly from clinical trials with highly selected patient 
populations. Reports on survival rates from population-based materials of PCNSL are scarce.12,14,15 
Whether the observed improved survival in clinical trials is reproducible in population-based 
materials of PCNSL, is largely unknown.     
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AIDS-related PCNSL 
The prognosis of PCNSL in AIDS patients is poorer than in immunocompetent patients.7,65 With 
supportive care only the reported median survival of AIDS-related PCNSL is 1-1.5 months.20,65,234 
Patients treated with  WBRT have a median survival of 2.0-5.5 months20,26,33,65,244,245 and in a few 
selected patients eligible for chemotherapy, survival of more than one year has been 
achieved.20,26,237,238 Furthermore, some patients receiving HAART have survived with PCNSL for 
more than two years.33,234-236 However, in spite of the improved survival observed in these promising 
reports, a significant prolongation of survival has not yet been observed in epidemiological studies 
of AIDS-related PCNSL, and the prognosis remains dismal in most patients.21,36 
3.9 Prognostic factors 
Non-AIDS PCNSL 
Age and performance status are universally accepted prognostic factors for non-AIDS PCNSL in the 
literature.45,60,61,170,188,246-248  
Prognostic models serving as guidelines to determine patient prognosis and appropriate therapy have 
been developed for PCNSL by different research groups.60,188,248 In these models, the presence of risk 
factors with a known independent impact on survival is used to identify different risk groups among 
PCNSL patients. The International Extranodal Lymphoma Study Group (IELSG) designed a 
prognostic scoring system based on five variables (age >60 years, Eastern Cooperative Oncology 
Group (ECOG) performance status >1, elevated LDH, elevated level of CSF protein, and 
involvement of deep regions of the brain) and identified three different risk groups with significantly 
different survival rates (Table 2).60 A simpler prognostic model was developed at Memorial Sloan-
Kettering Cancer Center.248 This model was based purely on the two prognostic factors: age (≤ 50 
years) and Karnofsky performance score (<70), identifying three risk groups that display 
significantly different survival rates (Table 2).248 The Nottingham/Barcelona prediction score 
identifies 4 risk groups based on the presence of 3 risk factors (age ≥60 years, ECOG performance 
status >1, and multifocal tumors and/or meningeal disease); these risk groups also display different 
survival rates (Table 2).188  
There has been some discussion as to which of these scoring systems that are most adequate and 
reliable.249,250 A prerequisite basis of these models is the inclusion of only the factors with an 
independent impact on survival. The prognostic role of the variables: elevated LDH, elevated CSF  
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protein, involvement of deep brain regions (included in the IELSG model), and number of lesions 
and or meningeal disease (included in the Nottingham/Barcelona model) has not been consistently 
reproduced by different groups,248,250 whereas age and performance status are consistently identified 
as independent prognostic factors in a wide variety of studies.45,60,61,170,188,246-248 Information regarding 
age and performance status is normally easy to obtain in retrospective series whereas information on 
serum LDH, CSF protein, and lesion number/location and or meningeal disease may be incomplete 
or missing; as a result, in retrospective studies, many of the patients can not be categorized using the 
IELSG score.60,248,249 The application of a uniform scoring model in the design and reporting of 
clinical trials may facilitate the critical comparison of therapeutic results from different trials, and 
may facilitate the selection of more promising therapeutic strategies for future trials.247  
Biochemical markers proposed as prognostic indicators are expression of Bcl-6, CD10, CD105, Ki-
67, p53, VEGF, and c-Myc; results are, however, conflicting and the findings need to be validated in 
larger studies (See also section 5.3.4).64,68,69,69-71,71,72,76-80,169 Also, pharmacokinetic variables such as 
Table 2  
Different prognostic scoring models for PCNSL 
  
  IELSG60 MSKCC248 Nottingham/Barcelona188 
  Poor prognostic factors Poor prognostic factors Poor prognostic factors 
 Age > 60 y  Age > 50 y  Age ≥ 60 y 
 ECOG performance status > 1 
Elevated serum LDH 
 KPS < 70  ECOG performance status     
> 1 
 Elevated CSF protein    
 Tumor located in deep 
structures 
   
Multifocal tumors and/or 
meningeal disease  
      
  Risk group Risk group Risk group 
 Group 1: 0 or 1  factors present  Group 1: Age < 50  Group 1: 0 factors present 
 Group 2: 2 or 3  factors present 
Group 3: 4 or 5  factors present 
 Group 2: Age > 50,  
        KPS ≥ 70 
 Group 2: 1 factors present 
Group 3: 2 factors present 
   Group 3: Age > 50,  
        KPS < 70 
 Group 4: 3 factors present 
      
  Survival: 2-Year Survival ± SD Median survival; y (95% CI) Median survival; y 
 Group 1: 80% ± 8%  Group 1: 8.5 (4.8-16.8)  Group 1: 4.6 
 Group 2: 48% ± 7%   Group 2: 3.2 (2.6-4.3)  Group 2: 3.4 
 Group 3: 15% ± 7%   Group 3: 1.1 (0.7-1.6)  Group 3: 2.7 
     Group 4: 0.1 
CI, confidence interval; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group 
performance status; IELSG, International Extranodal Lymphoma Study Group; KPS, Karnofsky 
performance status; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center; SD, 
standard deviation; y, years. 
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area under the curve of methotrexate and plasmatic creatinine clearance have been identified as 
prognostic factors in PCNSL.251  
AIDS-related PCNSL 
As in non-AIDS PCNSL, good performance status has favorable impact on survival in patients with 
AIDS-related PCNSL.252-254 Treatments shown to have a significant impact on survival are whole 
brain irradiation,20,21,33,234,235,244 combined chemo- and radiotherapy in selected patients,20 and 
HAART.33,234,235 Higher CD4 lymphocyte count is reported to have favorable impact on survival in 
some studies,26,33 but not in all.21,252  
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4. SPECIFIC BACKGROUND AND AIMS OF THE 
STUDY 
Specific background 
During the last decades discrepant reports have been published on incidence rates of both non-AIDS 
PCNSL and AIDS-related PCNSL.4,7-18 Although many of these reports are population-based,4,7,8,10-17 
none of the studies comprises the population of an entire country. Furthermore, very few are based 
on review of medical records of patients recorded in cancer registries.14,15 Review of medical records 
seems essential to ensure the validity of data from cancer registries, as exclusion rates of above 50% 
after review of medical records are reported.14,15 Also, some materials on non-AIDS PCNSL may 
have included patients with HIV-infections,11,12 potentially making the estimates of incidence rates 
inaccurate.   
In the treatment of non-AIDS PCNSL and AIDS-related PCNSL, a large number of different 
treatment regimens have been reported in the literature during the last decade.26,33,168,173,177,188-202 
However, there is almost a complete lack of prospective randomized trials on PCNSL,184,203 and the 
optimal treatment remains to be established.178 Varying regimens and differences in patient selection 
between clinical trials make the comparisons of survival difficult. Furthermore, as patients 
participating in clinical trials often are highly selected with younger age and better performance 
status, the results from these trials may not be applicable for the general patient population in a 
standard clinical setting. Very few retrospective studies have explored the treatment received and the 
outcome in population-based materials of PCNSL,12,14,15,162,204 but such studies are important to truly 
evaluate outcomes in a standard clinical setting. Whether the improved survival observed in clinical 
trials during the last decade is reproducible in population-based materials of PCNSL, is largely 
unknown.    
To ensure early treatment of PCNSL, early histological diagnosis is essential. Diagnosing PCNSL 
may be difficult in both AIDS patients and non-AIDS patients. Common debut symptoms such as 
personality change or symptoms of raised intracranial pressure46,47 are non-specific, and findings at 
CT and MR imaging are variable and may not suggest the diagnosis.113 Studies from the 80s and 
early 90s report median time spans from initial symptoms to final diagnosis of PCNSL of 1.5-5 
months in studies of non-AIDS patients47,85,86 and mean time spans of 3 months for non-AIDS and 2 
months for AIDS patients.65 Only few studies reporting such time spans have been population-
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based,85 and no study has comprised an entire country. Considering the advances in diagnostic 
imaging technologies during the last decades, these time spans may also have decreased.  
Imaging findings in non-AIDS PCNSL have mostly been investigated in single- or multicenter 
studies;45,48,96-102 population-based studies on imaging findings are scarce.14 Furthermore, with 
increasing incidence of PCNSL and advancing imaging technology, typical appearance at CT and 
MR imaging may have changed. Studies exploring temporal changes in imaging findings in non-
AIDS PCNSL are to date completely lacking in the literature.  
Aims of the study  
1. To investigate incidence, clinical features, and therapeutic outcome of non-AIDS PCNSL in 
Norway in 1989-2003 (Paper I and Paper III). To investigate time trends in incidence, 
clinical features, histological diagnosis, treatment, and outcome, and identify prognostic 
factors for all cases of histologically verified non-AIDS PCNSL diagnosed in Norway in 
1989-2003 (Paper III). 
2. To investigate incidence, clinical features, radiological findings, histological diagnosis, 
treatment, and outcome for all patients with histologically verified AIDS-related PCNSL 
diagnosed in Norway in 1989-2003 (Paper IV).  
3. To assess time from initial symptom to first neuroimaging and final morphological diagnosis 
in non-AIDS and AIDS-related PCNSL in Norway in 1989-1998. To explore potential 
associations between these time spans and recorded clinical and neuroimaging 
characteristics (Paper II).  
4. To describe the CT and MR imaging characteristics at presentation of non-AIDS PCNSL in 
Norway in 1989-2003. To investigate time trends concerning these imaging characteristics 
the consecutive 5-year periods; 1989-1993, 1994-1998, and 1999-2003. To identify possible 
associations between radiological findings and other patient characteristics, e.g. whether the 
patients were diagnosed while alive and time to diagnosis (Paper V). 
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5. MATERIALS AND METHODS 
Approval of the studies was obtained from The Directorate for Health and Social Affairs, The Data 
Inspectorate, and The Regional Committee for Medical Research Ethics. 
5.1 Patients 
In Norway, cancer reporting to the Norwegian Cancer Registry has been mandatory since 1952, 
making the registration of cancer in Norway rather comprehensive for more than 50 years. Lists of 
all patients diagnosed with PCNSL in Norway in 1989-1998 and 1989-2003 were obtained from the 
Norwegian Cancer Registry in 2001 (for the time period 1 January 1989 to 31 December 1998; 
n=101) and 2006 (for the time period 1 January 1989 to 31 December 2003; n=180). In order to go 
through the complete medical records of the patients, the author of this thesis visited the archives of 
medical records at the 6 major university hospitals in Norway (Rikshospitalet University Hospital, 
Ullevål University Hospital, the Norwegian Radium Hospital, Haukeland University Hospital, St. 
Olavs Hospital, and University Hospital of North Norway). These hospitals diagnosed and treated all 
but 8 of the 180 patients recorded in 1989-2003. The archives were visited twice; at the first visit in 
2002 data were collected for the time period 1989-1998. At the second visit in 2006, data were 
collected for the time period 1999-2003; due to updated recordings in the cancer registry, data on 12 
additional patients diagnosed in 1989-1998 were also obtained. Medical records from other treating 
hospitals were obtained by mail. 
The first review of the medical records was performed to identify all patients with morphologically 
verified (based on the pathological report) PCNSL in Norway in 1989-1998. There were 58 cases of 
non-AIDS PCNSL (described in Paper I and Paper II) and 16 cases of AIDS-related PCNSL 
(described in Paper II). For the time period 1989-2003, the patients were included on the basis of 
chart review and the results of histologic review of all available specimens in patients having 
conclusive of possible PCNSL as their primary histologic diagnosis (n=104): 98 cases of non-AIDS 
PCNSL were identified and described in Paper III. Four non-AIDS patients included in the patient 
samples from 1989-1998 (Paper I and II) were excluded from the patient sample from 1989-2003 
(Paper III, n=98) because of lack of histological verification at review (n=3) and inconclusive 
pathological report in a patient with no histological material available for review (n=1). Updated 
recordings at the Norwegian Cancer Registry revealed 3 additional cases of non-AIDS PCNSL and 3 
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cases of AIDS-related PCNSL diagnosed in 1989-1998 that were included in the patient samples in 
Paper III (n=98) and Paper IV (n=29), respectively.  
Of the 98 non-AIDS patients diagnosed in 1989-2003, 75 patients had radiological imaging prior to 
diagnosis available for review (Paper V). AIDS-related PCNSL was identified in 23 cases recorded 
at the Norwegian Cancer Registry, and additionally 6 patients were identified from the autopsy 
registry of AIDS patients at Ullevål University Hospital. All together we identified 29 patients with 
AIDS-related PCNSL in 1989-2003 in Norway, described in Paper IV.  The inclusion of patients 
investigated in the different papers in this thesis is specified in Table 3 and Figure 2. 
 
                                                                                                                                                              
                                               
Table 3 
Study characteristics of the various subgroups investigated in the papers included in this thesis.  
Paper Study design Inclusion of patients based on Number of 
cases 
Time period 
Paper I Population-
based 
Norwegian Cancer Registry; 
chart review 
58 1989-1998 
Paper II Population-
based 
Norwegian Cancer Registry; 
chart review 
74 1989-1998 
Paper III Population-
based 
Norwegian Cancer Registry; 
chart review, histologic review 
98 1989-2003 
Paper IV Population-
based 
Norwegian Cancer Registry and 
AIDS autopsy registry (Ullevål); 
chart review, histologic review 
29 1989-2003 
Paper V Population-
based 
Norwegian Cancer Registry; 
chart review, histologic review, 
radiological images available 
75 1989-2003 
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Figure 2 
Inclusion of patients based on chart review (paper I-II) and both chart review and histologic review 
(paper III-V). 
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5.2 Data collection  
5.2.1 Chart review 
The review of all medical records was performed by the candidate and information concerning 
clinical features, primary histological diagnosis, radiological findings, medical treatment, and 
outcome were registered according to a form designed for the purpose of the present study 
(Appendix). Briefly, these variables included: age, sex, former diseases, symptoms, diagnostic 
procedures, performance status at time of diagnosis, findings at examinations undertaken (including 
imaging), histological diagnosis, treatment (steroid medication, chemotherapy and/or radiotherapy), 
and outcome. Time of symptoms, examinations, diagnosis, treatment, and death were recorded in all 
patients.  
Performance status was assessed according to the World Health Organization (WHO) performance 
score which is identical to the Eastern Cooperative Oncology Group (ECOG) performance score 
and Zubrod score. These performance scores run from 0-5 with the different numbers indicating: 0, 
no symptoms; 1, symptomatic but completely ambulant; 2, symptomatic, <50% in bed during the 
day; 3, symptomatic, >50% in bed during the day but not chronically bedridden; 4, chronically 
bedridden requiring assistance with the activities of daily living; 5, death.255,256 Performance status 
when classified as ECOG 0-1 and 2-4 is equivalent to the Karnofsky Performance scores ≥70 and 
<70, respectively.147,256 Performance status at time of diagnosis was recorded when this was 
specified in the medical records; when this information was lacking, performance status was 
estimated retrospectively based on information in the medical record.  
5.2.2 Histologic review 
For non-AIDS patients, all available and relevant histological and cytological material of patients 
having conclusive or possible PCNSL as primary histological diagnosis (n=104) in 1989-2003 was 
collected and reviewed by one pathologist at Haukeland University Hospital, and for patients 
diagnosed at Rikshospitalet University Hospital (n=38) also by one of their pathologists. The 
material was reclassified according to the current WHO-classification (2001).257 Supplementary 
immunohistochemical and histochemical staining techniques (Giemsa stain, Periodic acid-Schiff and 
reticulin stain) were performed when required to confirm the diagnosis and/or reclassify the 
lymphomas. As a minimum the following antibodies were used for immunohistochemistry: CD20, 
CD79a, CD3, and Ki67. The following markers were used as required: CD45 (leukocyte common 
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antigen), CD43, CD30, CD138, CD23, CD10 (common acute lymphoblastic leukemia antigen), 
CD5, Cyclin D1, CD8, CD4, CD68, CD34, terminal deoxynucleotidyl transferase, CD56 (neural cell 
adhesion molecule), Kappa light chain, and Lambda light chain. 
A pathologist at Ullevål University Hospital reexamined the histologic material of the 29 patients 
recorded with AIDS-related PCNSL. In 2 patients the histologic material was collected from other 
hospitals; the remaining 27 had biopsy/autopsy material at Ullevål. The specimens (based on biopsy 
in 2 patients and autopsy in 27) were reclassified according to the current WHO-classification 
(2001).257 For immunohistochemistry, the antibodies CD3, CD20, and Ki67 were used as a 
minimum. Epstein-Barr virus hybridization was performed in 25 patients.  
5.2.3 Imaging review 
All radiological examinations of the brain in patients diagnosed with non-AIDS PCNSL (n=98) or 
AIDS-related PCNSL (n=29) in 1989-2003 in Norway were registered, and all available brain 
images were collected from treating hospitals and radiological departments. Film images were 
scanned and stored together with electronic images (on CDs/DVDs) in an electronic research 
archive.  
First CT and/or MRI (no more than 2 months apart) performed at presentation prior to histological 
diagnosis were reviewed. Hospitals in Norway are obliged to store radiological images for only 10 
years; thus, fewer patients had images available for review the first 5-year period of our study. 
Among patients diagnosed in 1989-1993 only 9 out of 31 (29%) had images available for review 
whereas 80 out of 96 (83%) patients diagnosed in 1994-2003 had images available for review. 
Altogether, 75 non-AIDS patients and 14 AIDS patients had imaging of the brain available for 
review.  
Among non-AIDS patients, 75 patients (35 male, 40 female) aged 13-83 (mean 64, median 67) years 
had primary imaging of the brain available for review (Paper V); 68 (91%) patients had contrast-
enhanced imaging (including non-contrast series in 58 patients) while 7 (9%) had non-contrast series 
only. CT images were reviewed in 66 patients (both contrast and non-contrast series in 46, only 
contrast series in 9 and only non-contrast series in 11). MR images were reviewed in 52 patients (T1-
weighted contrast and non-contrast series in 47, only non-contrast series in 3, only contrast series in 
2; T2-weighed series in 48); in 43 patients both CT and MR images were reviewed. For patients with 
both CT and MR images (n=43), median (mean; range) time from first imaging modality (CT in 39 
patients, MR imaging in 4 patients) to second imaging modality was 4 (8; 0-36) days. Median (mean; 
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range) time was 6 (14; 0-206) weeks from first symptom to first imaging and 3 (10; 0-125) weeks 
from first imaging to histological diagnosis. 
Among AIDS patients (Paper IV), CT images were reviewed in 14 patients (both contrast and non-
contrast series in 11, only contrast series in 3) and MRI in 4 patients (T1-weighted contrast and non-
contrast series in 2, only non-contrast series in 2; T2 weighed series in 4); 4 patients had a review of 
both CT and MRI. 
A neuroradiologist with 25 years experience and a general radiologist with 8 years experience (the 
author of this thesis) reviewed all CT and MR images in consensus, after first having performed 
independent reviews. They used a standardized registration form for each modality (Appendix) and 
had primary imaging reports available. The lesions were characterized (numbers, size, location, 
margins, oedema, mass effect, hemorrhage, attenuation/signal intensities relative to grey/white 
matter, and contrast enhancement) and the presence of no lesion, single focal lesion, multiple focal 
lesions, or disseminated lesions (i.e. irregularly margined innumerable confluent pathological lesions 
affecting multiple regions of the brain) was registered.  
Among patients with non-AIDS PCNSL, the radiological findings at CT (n=66) and MRI (n=52) 
(Paper V) were analyzed separately for the two modalities. We further composed a dataset intended 
to reflect findings at CT and/or MR imaging in the whole sample (n=75). For this dataset, findings at 
MR imaging were used when available. If MR imaging was performed without contrast series (n=3) 
or after steroid treatment (n=19) (which might have influenced imaging findings), findings at 
contrast-enhanced CT (prior to steroid treatment) were used instead. In 6 patients (out of 75) only 
post steroid treatment (median duration 4.5 days; range 2-13 days) imaging (MRI in all) was 
available. These patients had undergone imaging prior to steroid treatment, but the images were 
unavailable for review (n=5) or were unenhanced CT images only (n=1).  
5.2.4 Follow-up data 
Cause of death was established from medical records (available in 98/98 non-AIDS patients and 
29/29 AIDS patients), autopsy reports (autopsy performed in 27/98 non-AIDS patients and 27/29 
AIDS patients; reports available in all), and death certificates (available in 81/89 deceased non-AIDS 
patients and in 27/28 deceased AIDS patients). The recorded cause of death reported on the death-
certificate, was obtained from the Norwegian Cancer Registry. Follow-up data on long-term 
survivors concerning whether the patient was still alive was regularly obtained from the Patient 
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Information Management System (PiMS) (with access to the National Registry/Folkeregisteret) at 
Haukeland University Hospital. 
5.3 Statistical methods 
All p-values in the analyses are two-sided. The analyses were performed with Stata 9.0 (College 
Station, TX), SPSS 14.0 (Chicago, IL), StatXact, and S-plus. 
5.3.1 Associations and tests for trend 
The examination of associations for dichotomous variables was performed with Fischer’s exact test, 
and Mantel-Haenszel exact test was applied to analyze time trends in dichotomous variables for the 
5-year periods; 1989-1993, 1994-1998, and 1999-2003.  
For the comparison of continuous variables between different patient groups, the assumption of 
normal distribution was avoided, by using the non-parametric test Kruskal-Wallis Test for one way 
analysis of variance. Time trends for continuous variables for the 5-year periods 1989-1993, 1994-
1998, and 1999-2003 were analyzed using the non-parametric linear trend test Jonckheere-Terpstra 
test.  
5.3.2 Incidence rates 
We calculated incidence rates of non-AIDS PCNSL based on the number of new cases diagnosed 
with non-AIDS PCNSL each year and the population of Norway at Jan.1st the same year (Paper I 
and III). Trend test and 95% confidence interval (CI) for incidence was calculated according to the 
Poisson distribution. To estimate the average change in yearly incidence rate, estimated annual 
percent change (EAPC) was calculated by fitting a least-squares regression line to predict the natural 
logarithm of the yearly rates.  
We calculated absolute incidence rates of PCNSL among persons with AIDS based on numbers of 
newly diagnosed AIDS-related PCNSL and numbers of patients living with AIDS the same year 
(person year at risk) (data from The Norwegian Surveillance System for Communicable Diseases; 
MSIS) (Paper IV). Trend test and 95% confidence interval (CI) for incidence was calculated 
according to the Poisson distribution.  
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5.3.3 Survival analyses 
Duration of survival was calculated as time between date of diagnostic procedure (operation/ biopsy/ 
cytology) that led to histological diagnosis and date of death. Survival curves were calculated and 
plotted using the method of Kaplan and Meier.258 Log-Rank test was used for univariate comparison 
of survival between groups. The Cox proportional Hazard Model was used to study the effect on 
survival of several variables simultaneously and to estimate hazard ratios.259 The proportional hazard 
assumption was assessed by comparing the Cox model with a time dependent model.260  
In the analyses of diagnostic delay (Paper II), the method of Kaplan Meier258 was applied to analyze 
potential associations between different factors and time span and the Log-Rank test was used for 
univariate comparisons of time spans between groups. The Cox proportional Hazard Model was used 
to study the effect on time span of several factors simultaneously and to estimate hazard ratios.259 In 
the analyses of time to final diagnosis, patients diagnosed post-mortem were censored. 
 
 
 
 43 
6. MAIN RESULTS  
In Paper I we report incidence rate, clinical features, treatment, outcome, and prognostic factors of 
non-AIDS PCNSL in Norway in 1989-1998. We identified 58 cases of histologically verified non-
AIDS PCNSL. The average annual incidence rate was 1.34 cases per million with a non-significant 
increasing trend (p=0.069). For patients diagnosed while alive (n=45), estimated survival following 
histologic diagnosis was 55%, 47%, and 23% at 1 year, 2 years, and 5 years, respectively. Good 
performance status and active treatment had an independent favorable impact on survival.  
In Paper II we examine the time from first symptom to final morphological diagnosis of non-AIDS 
PCNSL (n=58) and AIDS-related PCNSL (n=16) in Norway in 1989-1998. The time from initial 
symptom to final morphological diagnosis of PCNSL had a median (mean, range) of 75 (157, 8-
1285) days in non-AIDS patients and 70 (106, 22-330) days in AIDS patients. Among non-AIDS 
patients, the time to diagnosis was longer in patients with no tumor in the first neuroimaging report 
after initial symptom (p=0.001). Median (mean, range) time from initial symptom to neuroimaging 
was 21 (88, 1-1095) days in non-AIDS patients and 14 (25, 1-60) days in AIDS patients. In the non-
AIDS group, those presenting with personality change or visual disturbance had more delayed 
imaging than the others. The time from first neuroimaging examination to final diagnosis in non-
AIDS patients had a median (mean, range) of 28 (69, 1-845) days, and was longer when no tumor 
was indicated in the imaging report (p=0.005) and if first biopsy did not confirm the diagnosis 
(p=0.02). All AIDS patients had their diagnosis of PCNSL first established by autopsy. The time 
from first neuroimaging to autopsy had a median (mean, range) of 48 (81, 10-270) days.  
In Paper III we analyze time trends in the incidence, clinical features, histologic diagnosis, 
treatment, and outcome of non-AIDS PCNSL in Norway from 1989 to 2003. We identified 98 
patients with confirmed, newly diagnosed non-AIDS PCNSL in this period. The incidence rate 
increased during the consecutive 5-year periods from 0.89 per million during 1989 to 1993, to 1.74 
per million during 1994 to 1998, and to 1.82 per million during 1999 to 2003 (p = 0.013). Diagnostic 
delay and overall survival did not improve with time. Survival decreased from 1999 to 2003 
compared with survival from 1994 to 1998, which was explained in part by reduced performance 
status and fewer patients receiving combined chemotherapy and radiotherapy during 1999 to 2003. 
In multivariate analysis, age </=50 years, a good performance status, and active treatment (especially 
combined chemotherapy and radiotherapy) significantly improved survival.  
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In Paper IV we investigate incidence, clinical features, treatment, and outcome of AIDS-related 
PCNSL diagnosed in Norway in 1989-2003. We identified 29 cases of histologically verified AIDS-
related PCNSL in this period. Only 2 of these cases were diagnosed while alive. AIDS patients in 
Norway had 5.5% lifetime risk of PCNSL, and their incidence rate of PCNSL per 100 person-years 
(1.7, 95%CI: 1.1-2.4) decreased during the consecutive 5-year periods from 3.6, to 2.5, and to 0.4 
(p<0.001). Median survival from initial symptom of PCNSL was 2.3 months; one patient was still 
alive 4 years after radiotherapy.  
In Paper V we investigate imaging findings at presentation of non-AIDS PCNSL in Norway in 
1989-2003; time trends in imaging characteristics the consecutive 5-year periods (1989-1993, 1994-
1998, and 1999-2003); and associations between radiological findings and patient characteristics. 
Review of CT and/or MRI in 75 patients with non-AIDS PCNSL revealed no lesion in 10 (13%), 
single focal lesion in 34 (45%), multiple focal lesions in 26 (35%), and disseminated lesions in 5 
(7%) patients. All together, 103 lesions were identified: 63% had white matter location, 56% abutted 
the ventricular surface, and 43% had frontal lobe location; 100% (102/102) enhanced (13% ring-
like) on contrast series. Except for smaller median diameter of the lesions observed the last time 
period (1999-2003), the imaging characteristics were practically unchanged during the consecutive 
5-year periods. When imaging findings were grouped into no lesion, single focal lesion, multiple 
focal lesions, or disseminated lesions, longer delay from imaging to diagnosis was observed in 
patients with no lesion (p=0.01) and patients with no or disseminated lesions were less often 
diagnosed while alive (p=0.06).  
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7. Discussion 
7.1 Methodological considerations 
7.1.1 Patient series 
Our patient series are based on recordings of all cases diagnosed with PCNSL in the Norwegian 
Cancer Registry in 1989-2003. These recordings were validated by thorough review of medical 
records and pathological material. This led to the exclusion of 59 (33%) out of 180 cases due to 
incorrect registration of PCNSL (n=41) or lack of histological verification (n=18). Our resulting 
patient series consisted of 98 non-AIDS PCNSLs and 23 AIDS-related PCNSLs diagnosed in 
Norway the current 15-year period.  
Despite mandatory cancer reporting to the Norwegian Cancer Registry, some cases may not be 
reported. A comprehensive search for non-reported cases of AIDS-related PCNSL in the autopsy 
registry at Ullevål University Hospital, led to the inclusion of 6 non-reported cases giving a total of 
29 cases of AIDS-related PCNSL.  An effective search for non-reported cases of non-AIDS PCNSL 
could not be performed, as other large registries of non-AIDS PCNSL do not exist, and these 
patients are diagnosed and treated at many different hospitals in Norway. By contrast, Ullevål 
University Hospital treated 59% (423/723) of the new cases of AIDS recorded at The Norwegian 
Surveillance System for Communicable Diseases (MSIS) and autopsied 67% (186/278) of their 
AIDS deaths during the studied 15-year period.  
Patients with no (n=12) or inconclusive (n=6) histological diagnosis were excluded irrespective of 
clinical and/or radiological findings suggestive of PCNSL. We can not rule out that some of these 
patients may have had PCNSL and were faulty excluded.  
On the other hand, some included patients may have had occult systemic lymphoma since adequate 
staging regimens were not performed in all of the patients. However, among non-AIDS patients an 
autopsy that excluded systemic lymphoma was performed in 28% (27/98). Of the remaining 71 
patients, 69 had a negative abdominal CT or ultrasound and 58 had a negative bone marrow biopsy. 
Among AIDS-patients 90% (26/29) had a complete autopsy of the entire body excluding systemic 
lymphoma. In the remaining 3 patients none had signs of lymphoma at chest- and abdominal imaging 
(n=3) or bone marrow biopsy (n=2). Thus, most of the patients not having an autopsy performed, 
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underwent relevant staging that excluded systemic lymphoma. Furthermore experiences from others 
indicate that systemic lymphoma masquerading as PCNSL is a relatively rare occurrence (in the 
order of 4%).148,149 All taken together, we consider the diagnosis of PCNSL in our patient series to be 
fairly well validated.  
A substantial proportion (33%) of the patients recorded as PCNSL in the Norwegian Cancer Registry 
was excluded. Similar experiences have been reported on PCNSL from other groups in which review 
of medical records led to the exclusion of above 50% of the patients recorded in cancer registries.14,15 
These findings underscore the importance of validating data from registries.   
7.1.2 Data on clinical characteristics and cause of death 
In all patients included in the materials of non-AIDS PCNSL (paper I, II, III and V) and AIDS-
related PCNSL (paper II and IV), the entire or essential parts of the medical records from one or 
more treating hospitals were obtainable. Clinical features, histological diagnosis, radiological 
findings, medical treatment, and outcome were registered. Most of these data were normally easy to 
extract from the medical records. However, for patients diagnosed with PCNSL while alive (80 non-
AIDS patients, 2 AIDS patients), performance status at time of histological diagnosis was specified 
in the medical records in only 39 of the non-AIDS patients, and this variable was therefore estimated 
retrospectively in 41 non-AIDS patients and 2 AIDS patients. This may have reduced the validity 
and accuracy of this variable.  
Debut of first symptom attributable to PCNSL was specifically dated in the medical records in most 
cases. However, for some patients, the time of first symptom was more vaguely reported and had to 
be estimated retrospectively, potentially reducing the validity of the variable. Furthermore, the 
different symptoms prior to the diagnosis of PCNSL were normally specified in the medical records. 
In patients having a relatively long time span from symptoms to diagnostic imaging suggesting a 
tumor and to final histological diagnosis, we can not unequivocally prove that these symptoms 
actually were attributable to PCNSL. However, most of the patients were formerly healthy and 
presented with new symptoms not explained by other conditions, making it likely that the symptoms 
were related to PCNSL.   
The cause of death in all included patients was established based on recordings in medical records 
and death certificates. The cause of death was not always directly stated in the medical records; in 
these cases, the cause of death was estimated based on clinical course and imaging findings prior to 
death reported in the medical records. In all cases with obtainable death certificate (81 out of 89 
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deceased non-AIDS patients, 27 out of 28 deceased AIDS patients), the cause of death given on the 
death certificate was in accordance with the cause of death based on recordings in the medical 
records. The recordings on cause of death in our material, thus seems quite well validated.   
7.1.3 Histological material 
The histological review was close to complete in this national material. Furthermore, supplementary 
immunohistochemical and histochemical staining techniques were performed when required to 
confirm the diagnosis and/or reclassify the lymphomas. In only two patients (both non-AIDS) no 
histological or cytological material was available for review. One of these patients was included 
based on the primary histological diagnosis (Precursor B-lymphoblastic lymphoma) recorded in the 
primary histological report; the other patient was excluded due to inconclusive diagnosis recorded in 
the primary histological report.  
7.1.4 Imaging material 
Most radiological images from 1989-1993 were unavailable, and this may have biased our analyses 
on imaging findings. However, the availability of images in patients diagnosed in 1994-1998 and 
1999-2003 was quite good, making this imaging rather representative for the time period 1994-2003. 
Furthermore, for non-AIDS patients, results on time trends for imaging findings for the 5-year 
periods 1989-1993, 1994-1998, and 1999-2003, were largely unchanged in an analysis restricted to 
the two last 5-year periods. This, and the stable imaging findings over time identified in the whole 
material, makes it unlikely that unavailable images have substantially biased our analyses on 
imaging findings.  
7.2 Discussion of results 
7.2.1 Incidence 
Non-AIDS PCNSL 
From the early 1980s increasing incidence rates of PCNSL have been reported in the non-AIDS 
population in some studies.4,7-10 In paper I and paper III we examined the incidence rates of non-
AIDS PCNSL in Norway in 1989-1998 and 1989-2003, respectively, and found an increasing trend 
for the time period 1989-1998 and significantly increasing incidence rates for the time period 1989-
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2003 (Figure 3). Our findings are in line with reports from the United States4,7-10 (from the time 
periods 1973-1984, 1981-1990, 1973-1992, 1958-1989, and 1973-1997, respectively), the United 
Kingdom11 (1973-1990), the Netherlands12 (1989-1994), and Japan13 (1989-2004). Stable incidence 
rates have, however, been found in Canada14 (1975-1996), Denmark15 (1983-1992), Scotland16 
(1991-1995), Hong Kong17 (1982-1997), and India18 (1985-1999). Although most if these reports are 
population-based,4,7,8,10-17 only two studies14,15 (reporting stable incidence rates) are based on review 
of medical records of the patients recorded in cancer registries. Furthermore, two studies11,12 
(reporting increasing incidence rates) may have included patients with HIV-infections. Thus, the 
discrepant findings from different parts of the world may be partly explained by methodological 
factors; nevertheless, true regional differences in the incidence of non-AIDS PCNSL most likely 
exist. So far, etiological factors explaining these differences remain to be identified.  
We found significantly increasing incidence rates of non-AIDS PCNSL in Norway from 0.89 per 
million in 1989-1993 to 1.74 per million in 1994-1998 and 1.82 per million in 1999-2003 (p=0.013). 
No changes concerning the registration of PCNSL in the Norwegian Cancer Registry have been 
carried out that could possibly bias this finding of increasing incidence. The proportion of patients 
excluded (39-55 %) did not vary much between the different 5-year periods, indicating no obvious 
changes in registration practice. The observed peak in new cases of PCNSL in 2003 (Figure 3) was 
odd but may be due to statistical variation within a rising trend. Omitting 2003 in the analysis, we 
still found significantly increasing incidence rates in 1989-2002 (p=0.023). The rising trend also 
seems to continue, as 2004 had the second largest number of cases recorded as PCNSL in the 
Norwegian Cancer Registry since 1989 (n=15 in 2004, n=20 in 2003).  
As immunocompromised patients with transplants or autoimmune conditions are predisposed to 
PCNSL,38 the frequent use of immunosuppressive medication the last years could theoretically 
account for an increasing incidence of PCNSL. However, in our material only 5 patients received 
immunosuppressive medication prior to first symptom attributable to PCNSL. When omitting these 
patients in the analyses, there was still a significant increase in annual incidence rate (p=0.006) and 
in incidence rates between the 5-year periods (p=0.021). 
It has been suggested that the observed increase in incidence of PCNSL may be partly due to 
improved technologies available for the diagnosis of brain tumor including CT and MRI.4 However, 
Olson et al. reported increasing PCNSL rates in the US that coincided with stable glioma rates when 
both tumors were being diagnosed with similar imaging technology.10 In Norway, the rates of CNS 
tumors almost doubled from 1970 to 1999.261 However, between 1989 and 2003 the increase in 
primary brain tumors (excluding tumors in meninges, corpus pineale, hypophysis, and cranial  
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Figure 3  
Incidence rates of non-AIDS PCNSL, NHL and primary brain tumors in Norway 1989-2003. EAPC, 
estimated annual percent change; NHL, non-Hodgkin’s lymphoma; PCNSL, primary central nervous 
system lymphoma. 
 
 
nerves) was moderate.262 The average annual incidence rate of primary brain tumors was 85.7 (95% 
CI: 83.4-87.9) per million and the estimated annual percent change (EAPC) was 2.3% (95% CI: 1.7-
2.9, p<0.001) (Figure 3). As the corresponding EAPC of non-AIDS PCNSL in our material (n=98) is 
7.3% (95% CI: 2.6-12.1, p=0.002), PCNSL increased relatively more than primary brain tumors. 
Although lack of a review of the medical records and histological material on all primary brain 
tumors gives a risk of misclassification that limits our ability to truly compare these EAPCs, it seems 
unlikely that the impact of improved diagnostic tools would explain the increasing incidence of 
PCNSL in Norway.   
The increased incidence of PCNSL also exceeds what may be caused by an increasing incidence of 
non-Hodgkin lymphomas in general. The average annual incidence rate of non-Hodgkin lymphoma 
in Norway during 1989-2003 was 143.9 (95% CI: 141.0-146.8) per million262 with an EAPC of only 
1.8% (95% CI: 1.3-2.2, p<0.001); far less than the EAPC of PCNSL (7.3%) (Figure 3). 
The average annual incidence rate of non-AIDS PCNSL in Norway in 1989-2003 was 1.49 per 
million (paper III). The corresponding incidence rates, reported from different parts of the world 
during the last two decades, range from 1.0-4.8 per million.4,7,10-12,14,15,17 The relative frequency of 
PCNSL compared to primary brain tumors in Norway in 1989-2003 was 1.7%. The corresponding 
figures in the literature range from 1.2-6.6%.9,12,15,18 These discrepant findings may be due to 
geographic differences in the epidemiology of PCNSL but also overestimation of incidence rates in 
some studies. While the study having the highest estimate on incidence rate (4.8 per million) based 
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their findings on recordings without a review of the medical records,10 two studies with lower 
estimates of incidence rate (1.1 and 1.6 per million) reported that a review of medical records led to 
an exclusion of above 50% of the recorded patients.14,15 Similarly, the review of medical records led 
to an exclusion of 59 (33%) out of 180 patients in our material. 
AIDS-related PCNSL 
As opposed to the dramatic increase in AIDS-related PCNSL observed in the 1980s and early 1990s,7,8 
the incidence of PCNSL among HIV infected patients has been reported to decline during the last 
decade in the era of HAART.19,22-25,32-35 In paper IV we examined the incidence of AIDS-related 
PCNSL in Norway. The absolute incidence rate of PCNSL among AIDS patients per 100 person-years 
in 1989-2003 was 1.7 (95%CI: 1.1-2.4) and decreased from 3.6, to 2.5, and to 0.4 the consecutive 5-year 
periods (p<0.001) with an EAPC of 18.6% (p<0.001) (Figure 4). The average annual incidence rate of 
AIDS-related PCNSL among inhabitants in Norway was 0.44 per million (95%CI: 0.30-0.64), and 
decreased with an EAPC of 8.9% (p=0.046) (Figure 4). Previous single- and multicenter studies22-24,33,34 
have also found decreasing incidence of AIDS-related PCNSL in the era of  HAART. However, to our 
knowledge, the present study is the first national survey to confirm these findings.  
The proportion of AIDS-deaths diagnosed with concomitant PCNSL was 5.5% (28/508). This 
proportion was stable over time (5.3% (12/227), 6.0% (13/215), and 4.6% (3/66) in 1989-1993, 1994-
1998, and 1999-2003). Our figures for incidence rate (1.7 per 100 person-years) and lifetime risk (5.5%) 
of PCNSL among AIDS patients are in the upper range of figures in other studies.7,20,22,26,111 Lower 
incidence rates have been reported from the US:7,22 the absolute incidence rate of brain lymphoma per 
1000 person-years among AIDS patients was 4.7 in 1981-19907 and 8.4 and 1.1 in 1988-1995 and 1996-
2000,22 respectively. Although not truly comparable with rates among AIDS patients, reported incidence 
rates of PCNSL per 1000 person-years among HIV-infected individuals in Europe were 0.3-5.3 in 1983-
200223 and 0.4-8.3 in 1994-2000.24 In the present study, the hospital (Ullevål University Hospital) 
treating 59% (423/723) of the reported new cases of AIDS in Norway, autopsied as much as 67% 
(186/278) of their AIDS deaths. This high autopsy rate far exceeds what is common in most countries,263 
and the high autopsy rate led to the identification of formerly missed cases of AIDS-related PCNSL, 
explaining why our figures on incidence rate are in the upper range. 
Autopsy studies of AIDS patients have identified PCNSL in as much as 9-14% of the patients.28-30 The 
proportion of AIDS-deaths diagnosed with concomitant PCNSL in Norway was 5.5% (28/508). Among 
patients diagnosed with AIDS-related PCNSL, 93% (27/29) had the diagnosis first established by 
autopsy. None of these patients had a biopsy performed while alive, and 15% (4/27) of them had no  
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Figure 4  
Annual incidence rates of AIDS-related PCNSL per million inhabitants and per 100 person year at 
risk (PYAR) for AIDS patients in Norway.  
 
 
focal brain lesion on imaging, so PCNSL was unexpected. Furthermore, PCNSL was considered a likely 
differential diagnosis prior to death in only 35% (8/23) of those with focal brain lesions, whereas 
cerebral toxoplasmosis was considered likely in 91% (21/23). Autopsy in all AIDS patients is thus 
needed to truly estimate the incidence of AIDS-related PCNSL in a population. 
7.2.2 Time to diagnosis 
Pitfalls in the interpretation of clinical, neuroimaging, and histological findings as well as indication 
or non-indication for diagnostic surgical procedures are well-known challenges in the management 
of possible brain tumors.264-267 In paper II we investigated time to diagnosis of PCNSL in Norway in 
the ten-year period 1989-1998. Among non-AIDS patients (n=58), those presenting with personality 
change or visual disturbance had more delayed first imaging than patients with other symptoms 
(epilepsy, cerebellar symptoms, focal neurological symptoms, or headache). Others have found that 
personality change may be the only symptom of PCNSL for a long time, and it may be 
 52 
misinterpreted as dementia or neurodegenerative disease.46 It has also been shown that patients with 
personality changes as dominating symptoms have delayed diagnosis of malignant glioma.268 
Symptoms and signs of visual disturbance have been reported in 8-10% of PCNSL patients5,46 and 
eye involvement by uveal or vitreal lymphoma often antedates the development of clinically evident 
brain lymphoma.5 Personality changes or eye symptoms involving uvea or corpus vitreum should 
thus, raise awareness of possible PCNSL. In our study the first imaging report indicated tumor in 5 
out of 8 non-AIDS patients imaged more than 3 months after the debut of personality change or 
visual disturbance. These patients might perhaps have profited from earlier imaging. 
To our knowledge, no former study of PCNSL has documented a relation between imaging findings 
and time to diagnosis. Time to diagnosis was longer in non-AIDS patients with no tumor in the first 
neuroimaging report (CT in 57 of 58 patients) after initial symptom (p=0.001) (paper II). Similarly, 
in paper V, when based on review of the imaging material in non-AIDS patients (1989-2003), 
patients with no lesion on imaging experienced a longer time to diagnosis of PCNSL (paper V). 
Non-diagnostic first biopsy also prolonged the time span from first neuroimaging to final diagnosis 
in non-AIDS patients (p=0.02) (paper II).  
In AIDS patients diagnosed in 1989-1998 (n=16), the time span from initial symptom to neuroimaging 
was relatively short (median 14 days), which could reflect an active attitude towards diagnosing 
concomitant disease in AIDS. However, the AIDS patients had strikingly long time spans from first 
neuroimaging examination to final diagnosis of PCNSL (median 48 days) (paper II). In only 7% (2/29) 
of the patients diagnosed with AIDS-related PCNSL in 1989-2003, the diagnosis was established while 
alive (paper IV). None of the remaining 27 patients first diagnosed at autopsy, had a biopsy performed 
while alive. All but 4 of these 27 patients had focal brain lesion(s) on CT/MR imaging, which should 
raise the suspicion of PCNSL. Furthermore, of 19 patients with focal lesion(s) who received toxoplasma 
therapy, only 2 showed a clear response. Nevertheless, none of these 19 patients underwent stereotactic 
or open biopsy which may be partly explained by the bad performance status (WHO 2-4) in most of 
them (79%, 15/19).   
Delayed diagnosis  of AIDS-related PCNSL is a concern with empiric toxoplasma therapy.26,270 To 
reduce this delay, brain biopsy is advised when there is clinical or radiological deterioration during the   
first week of initial toxoplasma therapy or lack of clinical improvement within 2 weeks.26,271  
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7.2.3 Imaging findings 
Non-AIDS PCNSL 
The findings at review of first CT and/or MR images, obtained after debut of first symptoms 
attributable to non-AIDS PCNSL in our population based material, ranged from no lesion (13% of 
patients), to single focal lesion (45%), multiple focal lesions (35%), and disseminated lesions (7%) 
(Paper V). Of the focal lesions (n=103), 63% had white matter location and 56% abutted the 
ventricular wall. These typical findings of single or multiple focal lesions in periventricular white 
matter are in accordance with previous single and multicenter studies.45,48,94-102,105,106,112 Also, our 
study confirmed that lesions are most frequent in the frontal lobes (in 49% of the patients in our 
study).45,48,96,100 We found enhancement in all single and multiple focal lesions examined with 
contrast series; other studies have shown enhancement in 97-99%.45,48,102  Ring-enhancement was 
found in 13% of the lesions; this is previously reported in 3-16% of lesions in non-AIDS 
PCNSL.48,66,96,99,100,102  
Concomitant hemorrhage in tumor was observed in 8% of the patients. One of these had tumor in a 
large chronic subdural hematoma; the remainder had a small hemorrhage identified at non-contrast 
T1-weighted MR images. Hemorrhagic lesion is an atypical finding in PCNSL, and it occurred more 
often in our study than in some materials (in 8% versus 2-4% of the patients).14,97 Small intratumoral 
hemorrhages were most common (prevalence 7%); this was also the case in a smaller study where 
small hemorrhages occurred in four (21%) of 19 lesions.106 
Disseminated lesions are a well-known atypical presentation of PCNSL,97,101 but it was more 
prevalent in our study than formerly reported (7% versus 1-3%)48,65 and might have been even more 
prevalent at histological examination. In one series, biopsy and autopsy material showed diffuse 
meningeal or periventricular involvement in 24%.5 Compared to autopsy, MR imaging seems to 
underestimate the tumor burden of PCNSL.116  
To our knowledge, no former study of PCNSL has documented a relation between imaging findings 
and whether the patient is diagnosed while alive. In paper V we showed that patients with no or 
disseminated lesions tended to be less likely to receive the diagnosis while alive. Although not 
formerly reported in PCNSL, delayed diagnosis following “negative” imaging has been documented 
in other malignancies.269 In our study (paper V), 5 of the 10 patients with no lesion underwent non-
contrast CT only at first imaging. Thus, relevant lesions might easily have been overlooked, and 
additional contrast series might have added valuable information. However, negative findings on 
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contrast enhanced CT do not exclude PCNSL.94,95 To ensure early detection and biopsy of lesions in 
suspected PCNSL, first imaging should include contrast enhanced MR imaging; this is considered 
the gold standard for imaging of brain tumors in National Comprehensive Cancer Network’s Clinical 
Practice Guidelines in Oncology.272 Furthermore, early renewed imaging should be considered when 
first imaging is negative and symptoms persist. 
The relative proportions of patients with no, single, multiple, or disseminated lesions at CT and/or 
MR imaging did not change significantly over time. The lesions had smaller median diameter 
(largest) the last 5-year period (p = 0.048); for all other variables regarding location, margins, 
oedema, mass effect, and contrast enhancement of lesions, no significant time trends were observed 
(p > 0.05). Thus, our hypothesis of changing imaging findings over time was not confirmed, except 
for lesion size. The smaller diameter of the lesions, observed the last time period, might be related to 
improved CT imaging and increased use of MR imaging, aiding in the detection of smaller lesions. 
Similarly, MR imaging has been shown to be superior to CT in the detection of metastases, with a 
reported mean maximal diameter of the lesions significantly smaller on MR imaging than on CT 
imaging.273,274   
AIDS-related PCNSL 
Among patients with AIDS-related PCNSL, multiple brain lesions on CT/MRI were found in 79% 
(11/14) of the patients having images available for review and 59% (17/29) of the patients based on 
imaging reports (paper IV). These figures are in the upper range of figures from other studies (31-
81%).33,65,109,110 Ring enhancement was observed in 75% (27/36 at CT and 6/8 at MRI) of the lesions 
(in 13 of the 14 patients at review). Such enhancement was thus more prevalent in our material than 
reported (52%) in a review of 32 series of AIDS-related PCNSL from 1980-1992 (n=315),65 and in a 
more recent study finding irregular peripheral enhancement in 73% and ring enhancement in only 
11% of the lesions.110 However, as ring enhancement may often be irregular and may resemble 
irregular peripheral enhancement, these discrepant findings may be due to different interpretations of 
enhancement patterns.  
The MRI/CT findings of AIDS-related PCNSL in our study are similar to those in toxoplasmosis.26,109 
MRI and CT can seldom differentiate PCNSL from toxoplasmosis.26,111 If available, diffusion or 
perfusion MRI, magnetic resonance spectroscopy, positron emission tomography and SPECT26,109 might 
help to select patients for biopsy versus empiric toxoplasma therapy. So might PCR examination of the 
CSF to detect Epstein-Barr virus DNA or Toxoplasma gondii DNA,26,28 but none of these tests are 
completely specific. Biopsy is often needed, but should be weighted against its relatively high 
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procedural risk in AIDS patients.26 Further research on the combination of less invasive diagnostic 
procedures is required to reduce the need for biopsy.  
7.2.4 Treatment 
Prior to 1997, there was no ongoing clinical trial on PCNSL in Norway. In 1997 the Nordic PCNSL 
Working Group introduced a phase II trial to investigate if durable responses could be obtained by a 
multiagent chemotherapy regimen.275 This treatment was based on HD-MTX 6 g/m2 in patients < 65 
years and HD-cytarabine 3 g/m2
 
in patients > 65 years; both age groups received carmustine, 
vincristine, dexamethasone and intrathecal treatment (cytarabine and MTX). This study was 
terminated after the enrollment of 30 patients due to five toxic deaths.275 In 2006 the Nordic PCNSL 
Working Group launched a phase II clinical trial on immunochemotherapy in PCNSL using 
rituximab, HD-MTX, HD-cytarabine, cyclophosphamide, ifosfamide, vincristine, vindesine, 
temozolomide and intrathecal cytarabine induction therapy in patients aged 18-75 years (followed by 
maintenance treatment with temozolomide in patients aged 66-75 years);276 no results on this trial 
have yet been published.   
Only 9 (2 in 1994-1998 and 7 in 1999-2003) out of the 80 non-AIDS patients diagnosed while alive 
in Norway in 1989-2003 (paper III), participated in a clinical trial.275 The remaining 71 non-AIDS 
patients were treated according to the ordinary clinical practice in Norway the current time period. 
Thus, the treatment of PCNSL in this non-AIDS population reflects the ordinary treatment practice 
in Norway, practically unaffected by any clinical trials, applied in an everyday clinical setting 
(Figure 5). The diversity of the treatment regimens applied, the limited size of our series, and the 
retrospective nature of our studies, did not allow a meaningful evaluation of an optimal treatment 
regimen for PCNSL. However, treatment with radiotherapy and/or chemotherapy had a significant 
favorable impact on survival in our study of non-AIDS PCNSL (paper III), as uniformly reported in 
the literature.168,169,178,187,228  
The optimal treatment of non-AIDS PCNSL remains controversial and is not standardized.178,203 In 
spite of numerous studies documenting the effect of chemotherapy and 
radiotherapy,153,158,161,163,164,168,173,177,188-202 the almost complete lack of prospective randomized studies 
on PCNSL makes it impossible to draw valid conclusions on the optimal treatment and the best 
timing of this treatment. Future prospective multicenter randomized trials are strongly warranted and 
crucial if these issues are to be addressed in the future.233,277 
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Figure 5 
Therapy received among patients diagnosed while alive with non-AIDS PCNSL in Norway in 1989-
2003. Chemotherapy included HD-MTX in 66% (only MTX in 28%; combined with other agents in 
38%). Radiotherapy consisted of whole brain irradiation in 100% and focal boost toward tumor in 
39%. 
 
Among patients with AIDS-related PCNSL, only two patients (7%; 2/29) had the diagnosis of 
PCNSL established while alive. These two patients received radiotherapy and were the only 
receiving adequate treatment for PCNSL. By contrast, in an Australian study of HIV-related PCNSL 
diagnosed in 1987-1998, more than 40% had biopsy and 49% received radiotherapy.33 This large 
difference is difficult to explain, but might suggest a more reluctant attitude towards invasive 
diagnostic procedures and treatment in our material. However, most of the AIDS patients in our 
study had a poor general condition, which could complicate diagnostic procedures and active 
therapy.  
7.2.5 Outcome and prognostic factors 
Among non-AIDS patients diagnosed while alive (n=80), the overall estimated survival from time of 
diagnosis was 46%, 38%, and 16% at 1, 2, and 5 years respectively, with a median survival of 7 
months (paper III). The estimated median survival was 44 months in patients receiving combined 
chemo- and radiotherapy versus 9 months and 4 months in patients receiving only radiotherapy and 
only chemotherapy, respectively. These survival rates are in the lower range of those reported by 
others.61,158,163,168,169,187,248 In our population-based material, fewer patients were ≤ 50 years than in 
many institution based materials; e.g., 14% of patients in our material compared with 30% of 
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patients in a material from a tertiary referral center.248 As young age is a well-documented favorable 
prognostic factor,45,60,61,247,248 differences in patient age may partly explain the discrepant findings on 
survival. 
The overall survival among non-AIDS patient diagnosed while alive the three 5-year periods did not 
improve with time (paper III). Considering the therapeutic advances reported  in clinical trials 
during the last decades,167,228 this was rather unexpected. However, our findings are in accordance 
with two recent population-based studies from the US (1975-1999)162 and Canada (1990-2003)204 
reporting stable outcomes in the studied periods. By contrast, a large study from Japan (1985-
1999)278 reported improved survival with time; this was partly explained by a significantly higher 
proportion of patients with good performance status treated during 1995-1999. Thus, the improved 
survival of PCNSL achieved in clinical studies with largely selected study samples, are not 
convincingly reproduced in population-based studies on PCNSL. Substantial obstacles might exist in 
the implementation of advanced treatment and care in the ordinary clinical practice in a population-
based setting.  
In paper III we examined prognostic factors among non-AIDS patients diagnosed while alive. As 
reported in most other studies, good performance status and young age had favorable independent 
impact on survival;45,60,61,247,248 patients receiving only symptomatic therapy had shorter 
survival,168,169,228 and combined chemo- and radiotherapy was superior to chemotherapy178 or 
radiotherapy alone.187 In our study, HD-MTX- containing regimen was highly significant (p=0.006) 
and year of diagnosis and total radiation dose (≥45 Gy) almost significant (p=0.06 and p=0.08, 
respectively) prognostic factors in the univariate analyses. However, none of these three variables 
reached statistical significance when included in a multivariate model. Omission of HD-MTX in the 
chemotherapy regimen tended to reduce survival (hazard ratio: 1.50, 95% CI: 0.76-2.96, p=0.24) 
(paper III); two studies have reported significant impact of HD-MTX on survival with hazard ratios 
of 2.3204 and 1.48.187 Reducing the radiotherapy dose (from 45 Gy to 30.6 Gy) in patients aged <60 
years may be associated with an increased risk of recurrence and lower overall survival;171 however, 
in our study the impact of radiation dose on survival was not significant in the multivariate analysis 
(hazard ratio: 1.33, 95% CI: 0.53-3.36, p=0.55). 
In the analyses of prognostic factors, the most common categorization of WHO performance score is 
0-1 versus 2-4,60,188,248 and this categorization was performed in paper III. Differently, we 
categorized performance status into 0-2 versus 3-4 in paper I. Nevertheless, also in paper I did 
good performance status (0-2) significantly improve survival both in the univariate (p<0.001) and in 
the multivariate analyses (hazard ratio: 2.39, 95% CI: 1.13-5.09, p=0.023). 
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Among AIDS patients median survival from first symptom attributable to PCNSL was 2.3 (95% CI: 1.5-
3.2) months, and only 21% (6/29) and 7% (2/29) were alive at 6 months and 1 year, respectively (Paper 
IV). The short median survival from first symptom attributable to PCNSL (2.3 months) is similar to 
survival times in other larger materials (1.0-2.8 months).21,33,36 However, long time survival of more than 
4.5 years was achieved in one patient treated with radiotherapy and HAART. Similar cases have been 
reported by others.234,236 The possibility of long term survival should prompt more aggressive 
diagnostics in suspected PCNSL. 
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8. Conclusions 
We identified an increasing incidence of non-AIDS PCNSL in Norway during 1989-2003 (paper I 
and paper III). For patients diagnosed while alive, the median survival from time of diagnosis was 7 
months, and young age (≤ 50 years), good performance status (WHO 0-1), and active treatment 
(especially combined chemo- and radiotherapy) significantly improved survival (paper III). For 
patients diagnosed at death, the median survival from time of initial symptom was 3 months. Despite 
diagnostic and therapeutic advances over the last decades, neither a reduction in diagnostic delay nor 
any improvement in overall survival with time was observed during the time period 1989-2003. 
Survival the last 5-year period (1999-2003) rather decreased compared to the preceding 5-year 
period (1994-1998), explained in part by worsened performance status and fewer patients receiving 
combined chemo- and radiotherapy. To achieve improved survival, better treatment and care must be 
implemented in ordinary clinical practice.  
We found decreasing incidence of AIDS-related PCNSL in Norway during 1989-2003 (Paper IV). 
Only 2 out of 29 patients had the diagnosis of AIDS-related PCNSL established while alive. AIDS 
patients had a 5.5% lifetime risk of PCNSL, emphasizing the importance of PCNSL as organ-
specific manifestation of AIDS. Despite dismal survival in most patients (median survival from 
initial symptom of PCNSL was 2.3 months), long term survival was achieved in one patient treated 
with radiotherapy and HAART. The possibility of long term survival should prompt more aggressive 
diagnostics in suspected PCNSL. 
We have identified considerable delays in the diagnosis of PCNSL during 1989-1998; time from 
initial symptom to final morphological diagnosis had a median (mean, range) of 75 (157, 8-1285) 
days in non-AIDS patients and 70 (106, 22-330) days in AIDS patients (paper II).  Non-AIDS 
patients with personality change or visual disturbance as initial clinical symptom had particularly 
delayed first neuroimaging, and those with no tumor reported on initial neuroimaging or with non-
diagnostic first biopsy had particularly delayed histopathological diagnosis of PCNSL. Physicians 
should consider early neuroimaging in patients with personality changes or visual disturbance, early 
renewed imaging in patients with persistent neurological symptoms but no tumor on initial imaging, 
and early/repeated biopsy of focal brain lesions in both AIDS patients and non-AIDS patients.  
CT and MR imaging at presentation of non-AIDS PCNSL in Norway in 1989-2003, typically 
revealed contrast-enhancing single (45%) or multiple (35%) focal lesions (paper V). No or 
disseminated lesions were also common (in 20%) and resulted in later histopathological diagnosis. 
 60 
We observed a smaller diameter of the lesions the last time period (1999-2003); this might be related 
to increased use of MR imaging and improved CT imaging, aiding in the detection of smaller 
lesions. To ensure early diagnosis of PCNSL, first imaging should include contrast enhanced MR 
series. Early renewed imaging should be considered when first imaging is negative and symptoms 
persist. In the era of increasing incidence of non-AIDS PCNSL, its features on imaging remain 
practically unchanged.  
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